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AbsTrACT
These guidelines on the management of primary 
sclerosing cholangitis (PSC) were commissioned by 
the British Society of Gastroenterology liver section. 
The guideline writing committee included medical 
representatives from hepatology and gastroenterology 
groups as well as patient representatives from PSC 
Support. The guidelines aim to support general 
physicians, gastroenterologists and surgeons in 
managing adults with PSC or those presenting with 
similar cholangiopathies which may mimic PSC, such as 
IgG4 sclerosing cholangitis. It also acts as a reference 
for patients with PSC to help them understand their own 
management. Quality of evidence is presented using 
the AGREE II format. Guidance is meant to be used as a 
reference rather than for rigid protocol-based care as we 
understand that management of patients often requires 
individual patient-centred considerations.
ExECuTivE summAry And 
rECommEndATions
There are many causes of cholangiopathy and these 
should be considered in the assessment of all patients 
presenting with biliary strictures. Primary sclerosing 
cholangitis (PSC) has a wide spectrum of symptom-
atology and stages of disease. Diagnosis is based 
on the cholangiographic (or histological) features 
of sclerosing cholangitis in the absence of identifi-
able causes of secondary sclerosing cholangitis. The 
diagnosis and management of PSC can be difficult 
and requires specialist referral for advanced disease 
or patients experiencing significant clinical events. 
Few randomised controlled trials have been carried 
out to define best management. Most recommen-
dations derive from small case –control studies, 
retrospective series and expert opinion. There is 
little evidence for the use of medical therapy to 
prevent progression of disease. Ursodeoxycholic 
acid is not recommended for routine use in newly 
diagnosed PSC. Non-invasive investigations such 
as magnetic resonance cholangiopancreatography 
(MRCP), dynamic liver MRI and/or contrast CT 
should be performed in patients who have new 
or changing symptoms or evolving abnormali-
ties in laboratory investigations. Worsening liver 
biochemistry and/or new high grade or evolving 
strictures should prompt further investigation for 
cholangiocarcinoma (CCA). Patients with PSC 
should ordinarily not undergo endoscopic retro-
grade cholangiopancreatography (ERCP) until 
there has been expert multidisciplinary assessment 
to justify endoscopic intervention. Colitis should be 
sought in all patients with PSC using colonoscopy 
and colonic biopsies. Patients with colitis should 
then have annual surveillance colonoscopy because 
of the increased risk of colorectal cancer. In these 
guidelines, we also review the management of PSC 
overlap syndromes and IgG4-related sclerosing 
cholangitis (IgG4-SC).
List of recommendations
1. There are multiple causes of cholangiopathy. 
We recommend that cholestatic liver biochem-
istry with typical cholangiographic features 
in the absence of other identifiable causes of 
secondary sclerosing cholangitis is usually 
sufficient for a diagnosis of PSC (strength 
of recommendation: STRONG; quality of 
evidence: MODERATE).
2. We recommend that MRCP should be the prin-
cipal imaging modality for the investigation of 
suspected PSC. ERCP should be reserved for 
patients with biliary strictures requiring tissue 
acquisition (eg, cytological brushings) or where 
therapeutic intervention is indicated (strength 
of recommendation: STRONG; quality of ev-
idence: HIGH).
3. We recommend that liver biopsy is normally 
reserved for possible small duct PSC, assess-
ment of suspected possible overlap variants 
or instances where the diagnosis is unclear 
(strength of recommendation: STRONG; quali-
ty of evidence: MODERATE).
4. We recommend risk stratification based on 
non-invasive assessment. Clinical scores are 
an emerging theme but no single method can 
be recommended at present to predict indi-
vidual patient prognosis. Given the unpre-
dictable disease course and the serious nature 
of the complications of PSC, patients should 
receive lifelong follow-up (strength of recom-
mendation: STRONG; quality of evidence: 
VERY LOW).
5.  We recommend that ursodeoxycholic acid 
(UDCA) is not used for the routine treatment 
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of newly diagnosed PSC (strength of recommendation: 
STRONG; quality of evidence: GOOD). For patients al-
ready established on UDCA therapy, there may be evidence 
of harm in patients taking high dose UDCA 28–30 mg/kg/
day (strength of recommendation: WEAK; quality of evi-
dence: LOW).
6. We recommend that UDCA is not used for the prevention of 
colorectal cancer or cholangiocarcinoma (strength of recom-
mendation: STRONG; quality of evidence: HIGH).
7. We recommend that corticosteroids and immunosuppres-
sants are not indicated for the treatment of classic PSC 
(strength of recommendation: STRONG; quality of evi-
dence: HIGH). In those patients with additional features 
of autoimmune hepatitis (AIH) or IgG4-related sclerosing 
cholangitis (IgG4-SC), corticosteroids may be indicated 
(strength of recommendation: STRONG; quality of evi-
dence: MODERATE).
8. We recommend that endoscopic screening for oesophageal 
varices should be done in line with international guidelines 
where there is evidence of cirrhosis and/or portal hyper-
tension (strength of recommendation: STRONG; quality of 
evidence: HIGH).
9. We recommend that colitis should be sought in all patients 
with PSC using colonoscopy and colonic biopsies (strength 
of recommendation: STRONG; quality of evidence: 
MODERATE).
10. We recommend that patients with suspected PSC under-
going ERCP should receive prophylactic antibiotics 
(strength of recommendation: STRONG; quality of evidence: 
MODERATE).
11. We recommend that non-invasive investigations such as 
MRCP, dynamic liver MRI and/or contrast CT should be 
performed in patients who have new or changing symp-
toms or evolving abnormalities in laboratory investiga-
tions (strength of recommendation: STRONG; quality of 
evidence: MODERATE).
12. We recommend that patients with PSC should ordinarily 
not undergo ERCP until there has been expert multidiscipli-
nary assessment to justify endoscopic intervention (strength 
of recommendation: STRONG; quality of evidence: 
MODERATE).
13. We recommend that in patients undergoing ERCP for domi-
nant strictures, pathological sampling of suspicious stric-
tures is mandatory (strength of recommendation: STRONG; 
quality of evidence: STRONG).
14. We recommend that in patients undergoing ERCP for domi-
nant strictures, biliary dilatation is preferred to the insertion 
of biliary stents (strength of recommendation: STRONG; 
quality of evidence: MODERATE).
15. We suggest that provision of care should involve a part-
nership between patients, primary care and hospital-led 
specialty medicine with consideration made with regard 
to patient risk assessment, symptom burden and how 
local services are configured (strength of recommendation: 
WEAK; quality of evidence: LOW).
16. We recommend that patients with symptomatic, evolving 
or complex disease should be referred for expert multidis-
ciplinary assessment. Patients with early, stable disease can 
be managed in general clinics (strength of recommendation: 
STRONG; quality of evidence: LOW).
17. We suggest that patients with PSC meeting inclusion criteria 
should be offered referral to a centre participating in clin-
ical trials (strength of recommendation: WEAK; quality of 
evidence: LOW).
18. PSC is a well-recognised indication for liver transplanta-
tion. We recommend that eligibility and referral should 
be assessed in line with the national guidelines (strength of 
recommendation: STRONG; quality of evidence: HIGH).
19. We recommend that all patients with PSC should have a 
risk assessment for osteoporosis. Once osteoporosis is 
detected, treatment and follow-up should be in accord-
ance with national guidelines (strength of recommendation: 
STRONG; quality of evidence: MODERATE).
20. Poor nutrition and fat-soluble vitamin deficiency are rela-
tively common in advanced PSC and we suggest that clini-
cians should have a low threshold for empirical replacement 
(strength of recommendation: WEAK; quality of evidence: 
MODERATE).
21. We recommend that in patients with fatigue, alternative 
causes should be actively sought and treated (strength of 
recommendation: STRONG; quality of evidence: LOW).
22. We suggest that cholestyramine (or similar) is first-line 
medical treatment for pruritus. Rifampicin and naltrexone 
are second-line treatments (strength of recommendation: 
WEAK; quality of evidence: LOW).
23. We suggest that an elevated CA19.9 may support a diag-
nosis of suspected cholangiocarcinoma but has a low diag-
nostic accuracy. Routine measurement of serum CA19.9 is 
not recommended for surveillance for cholangiocarcinoma 
in PSC (strength of recommendation: WEAK; quality of 
evidence: MODERATE).
24. We recommend that when a diagnosis of cholangiocarci-
noma is clinically suspected, referral for specialist multi-
disciplinary meeting (MDM) review is essential (strength 
of recommendation: STRONG; quality of evidence: 
MODERATE).
25. We recommend that where cholangiocarcinoma is 
suspected, contrast-enhanced, cross-sectional imaging 
remains the initial preferred investigation for diagnosis and 
staging (strength of recommendation: STRONG; quality 
of evidence: HIGH). Confirmatory diagnosis relies on 
histology with the approach to tissue sampling guided by 
MDM review. Options include ERCP-guided biliary brush 
cytology/fluorescence in situ hybridisation (FISH)/endobil-
iary biopsy/cholangioscopy/endoscopic ultrasound (EUS)-
guided biopsy and/or percutaneous biopsy (strength of 
recommendation: STRONG; quality of evidence: HIGH).
26. We suggest that an annual ultrasound scan of the gall-
bladder should be performed in patients with PSC. If polyps 
are identified, treatment should be directed by specialist 
hepatopancreaticobiliary (HPB) MDM (strength of recom-
mendation: WEAK; quality of evidence: LOW).
27. We recommend that patients with PSC who have coexistent 
colonic inflammatory bowel disease (IBD) should have 
annual colonoscopic surveillance from the time of diagnosis 
of colitis in line with the British Society of Gastroenterology 
(BSG) guidelines (strength of recommendation: STRONG; 
quality of evidence: HIGH). We suggest that those without 
IBD may benefit from less frequent 5-year colonoscopy or 
earlier in the advent of new symptoms (strength of recom-
mendation: WEAK; quality of evidence: VERY LOW).
28. We suggest that in the presence of cirrhosis, hepatocellular 
carcinoma surveillance should be carried out in accordance 
with international guidelines (strength of recommendation: 
WEAK; quality of evidence: LOW).
29. We recommend that because pregnancy in cirrhotic 
patients carries a higher risk of maternal and fetal compli-
cations, patients should have preconception counselling 
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and specialist monitoring (strength of recommendation: 
STRONG; quality of evidence: LOW).
30. We recommend that patients with PSC should be encour-
aged to participate in patient support groups (strength of 
recommendation: STRONG; quality of evidence: VERY 
LOW).
igG4-related sclerosing cholangitis (igG4-sC)
1. We recommend that elevated serum IgG4 levels support the 
diagnosis of clinically suspected IgG4-related disease (IgG4-
RD) but cannot be relied on for making a definite diagnosis, 
or distinguishing IgG4-SC from PSC (strength of recommen-
dation: STRONG; quality of evidence: MODERATE).
2. We recommend that in patients with suspected IgG4-SC, at-
tempts should be made to obtain a confirmatory histological 
diagnosis (strength of recommendation: STRONG; quality of 
evidence: MODERATE).
3. We recommend that other organ involvement (in particular, 
pancreatic manifestations of IgG4-RD) may provide import-
ant information to distinguish IgG4-SC from PSC (strength 
of recommendation: STRONG; quality of evidence: MOD-
ERATE).
4. We recommend that IgG4-SC should be diagnosed accord-
ing to the recommendations of the international consensus 
guidelines (strength of recommendation: STRONG; quality 
of evidence: MODERATE).
5. We recommend that patients with active IgG4–SC should be 
given corticosteroids as first-line treatment (strength of rec-
ommendation: STRONG; quality of evidence: MODERATE).
6. We recommend that all patients with IgG4-SC, including 
those with multiorgan involvement in IgG4-RD, should 
be considered for continued immunosuppressive therapy 
(strength of recommendation: STRONG; quality of evidence: 
MODERATE).
7. We recommend that patients with complex IgG4-SC and 
those with suspected malignancy should be referred to a 
specialist MDM for review (strength of recommendation: 
STRONG; quality of evidence: LOW).
sCopE And purposE
These guidelines have been commissioned on behalf of the British 
Society of Gastroenterology (BSG) liver section and UK-PSC 
with the aim of assisting clinicians in the diagnosis and manage-
ment of patients with PSC. Members of the writing committee 
included gastroenterologists, hepatologists, transplant physi-
cians and patient representatives. Where possible, clear, clini-
cally applicable recommendations are provided. The guidelines 
were reviewed by the BSG guideline commissioning group and 
council before circulation for international peer review. This 
document should be used in conjunction with other BSG guide-
lines and documents published by other international bodies in 
the USA, Europe and Japan.1–4 We recommend revision of the 
guidelines in 5 years. Where possible, we have tried to avoid 
duplicating advice published in related BSG guidelines.
EvidEnCE bAsE
These guidelines have been produced using systematic review of 
publications identified using PubMed, Medline and Cochrane 
database searches in line with the Appraisal of Guidelines for 
Research and Evaluation (AGREE) instrument II ( www. agreetrust. 
org). The primary keywords for baseline searches were ‘primary 
sclerosing cholangitis’, ‘autoimmune pancreatitis’, 'IgG4,’ 
'autoimmune overlap syndrome’ and ‘cholangiocarcinoma’. 
Additional keywords were included for specific searches such as 
therapy, ursodeoxycholic acid, ERCP, endotherapy, biliary dila-
tation, etc. The literature search was updated and completed in 
March 2018 before submission for peer review. Where possible, 
guidance is based on the highest levels of evidence available and 
cited. Where no high-quality studies or clear evidence exist, 
guidance is based on the majority consensus advice of expert 
opinion in the literature and the writing committee.
Grade of evidence is presented as ‘strong’ and ‘weak’ according 
to the international GRADE3 4 system:
 ► High-quality evidence: The authors are very confident that 
the estimate presented lies very close to the true value. One 
could interpret it as: there is very low probability of further 
research completely changing the presented conclusions.
 ► Moderate-quality evidence: The authors are confident that 
the presented estimate lies close to the true value, but it is 
also possible that it may be substantially different. One could 
also interpret it as: further research may completely change 
the conclusions.
 ► Low-quality evidence: The authors are not confident of 
the effect estimate and the true value may be substantially 
different. One could interpret it as: further research is likely 
to change the presented conclusions completely.
 ► Very low-quality evidence: The authors do not have any 
confidence in the estimate and it is likely that the true value 
is substantially different from it. One could interpret it 
as: new research will most probably change the presented 
conclusions completely.
bACkGround
definitions
PSC is an immune-mediated chronic liver disease characterised 
by inflammation, fibrosis and destruction of intrahepatic and/or 
extrahepatic bile ducts leading to cholestasis, bile duct strictures 
and hepatic fibrosis, which in turn may progress to cirrhosis, 
portal hypertension and hepatic decompensation.5 6 A variant 
known as small duct PSC is characterised by typical cholestatic 
liver biochemistry and histological findings typical of PSC but 
with normal appearance of the bile ducts at cholangiography.7 
PSC overlap/variant syndromes are conditions with diagnostic 
features of both PSC and other immune-mediated liver diseases, 
including autoimmune hepatitis (AIH). These guidelines refer 
specifically to PSC and its overlap syndromes, and include discus-
sion of IgG4-related sclerosing cholangitis, which can mimic 
PSC. Causes of secondary sclerosing cholangitis related to other 
identifiable causes of biliary obstruction leading to injury of the 
bile ducts are listed in box 1 but are not considered further.
Epidemiology
Population-based studies estimate the incidence of PSC to be 
0.91 to 1.3 per 100 000 person-years and may be increasing.8–12 
The incidence of small duct PSC is reported to be 0.15 per 
100 000 person-years.9 These studies were undertaken in popu-
lations of northern European descent in whom the incidence is 
thought to be highest. The incidence in most other ethnic groups 
is less clear.
Aetiology
PSC is a progressive biliary disorder strongly associated with 
inflammatory bowel disease (IBD). The genetic associations 
with disease risk, presence of chronic inflammation in the portal 
tracts and the strong association with IBD suggest that PSC is 
an immune-mediated disease, in which the biliary epithelial cell 
 o
n
 19 June 2019 by guest. Protected by copyright.
http://gut.bmj.com/
G
ut: first published as 10.1136/gutjnl-2018-317993 on 1 June 2019. Downloaded from 
4 Chapman MH, et al. Gut 2019;0:1–23. doi:10.1136/gutjnl-2018-317993
Guidelines
is a key cell targeted. However, no reliable autoantibodies have 
been identified and there is no significant response to immu-
nosuppression. To date, genome-wide studies have uncovered 
susceptibility loci for PSC-IBD, the majority of which have been 
previously reported as risk factors in other immune-mediated 
disorders. The strongest association resides within the human 
leucocyte antigen complex and suggests that disease-specific 
antigens drive pathogenic immune responses. Genetic determi-
nants account for <10% of total disease liability in PSC-IBD, 
clearly emphasising the predominant role of environmental 
factors on ultimate disease susceptibility.
How is psC diAGnosEd?
Consensus diagnostic criteria for PSC have been published as 
a workshop summary on behalf of the American College of 
Gastroenterology.1 Consensus guidelines relating to IgG4-SC, 
the biliary manifestation of IgG4-related disease (IgG4-RD),13 
and on PSC/AIH variant syndrome, have also been published.14 
A summary is outlined in figure 1. 
modes of presentation
Symptoms are rare in early disease. In more established cases, 
symptoms such as right upper quadrant pain, pruritus, fatigue, 
jaundice, fever and weight loss are present in 47–56% of 
patients.11 15 Patients usually present in one of several ways: (i) 
no symptoms or signs but with an incidental finding of abnormal 
liver biochemistry, (ii) biochemical screening of patients with 
newly diagnosed or pre-existing IBD, (iii) jaundice and pruritus 
secondary to cholestasis, (iv) cholangitis, (v) jaundice secondary 
Figure 1 Algorithm for the management of suspected primary sclerosing cholangitis.
box 1 Causes of secondary sclerosing cholangitis and 
conditions with cholangiographic features that may mimic 
biliary strictures
 ► Cholangiocarcinoma
 ► IgG4-SC
 ► Traumatic or ischaemic bile duct injury
 ► Choledocholithiasis
 ► Hilar lymphadenopathy
 ► Ampullary or pancreatic cancer
 ► Acute or chronic pancreatitis
 ► Choledochal varices (portal biliopathy)
 ► HIV cholangiopathy
 ► Chronic biliary infestation (liver fluke, ascaris)
 ► Congenital (choledochal cysts, biliary atresia)
 ► Papillary stenosis
 ► Critical illness ischaemic cholangiopathy
 ► Recurrent pyogenic cholangitis
 ► Hereditary haemorrhagic telangiectasia
 ► Systemic mastocytosis
 ► Langerhans' cell histiocytosis X
 ► Drugs
 o
n
 19 June 2019 by guest. Protected by copyright.
http://gut.bmj.com/
G
ut: first published as 10.1136/gutjnl-2018-317993 on 1 June 2019. Downloaded from 
5Chapman MH, et al. Gut 2019;0:1–23. doi:10.1136/gutjnl-2018-317993
Guidelines
to liver failure, (vi) variceal bleeding and/or ascites from portal 
hypertension or (vii) cholangiocarcinoma (CCA).
blood tests
Serum liver biochemistry tests are abnormal in approximately 
75% of patients with PSC.1 The most common pattern is of 
a cholestatic picture with raised alkaline phosphatase (ALP) 
and γ-glutamyl transpeptidase. An elevated serum bilirubin 
is reported to be present in 28–40% and is a marker of poor 
prognosis,15–17 but this is likely to be an overestimate with more 
advanced cases reported by published series. An elevated ALP 
is a sensitive marker for diagnosis but is not specific. Aspartate 
aminotransferase (AST) and alanine aminotransferase (ALT) are 
often mildly raised and do not necessarily suggest additional 
features of autoimmune hepatitis. As with other causes of liver 
disease, a raised AST>ALT may be an indicator of cirrhosis and 
poor prognosis.18 Other indicators of cirrhosis or portal hyper-
tension include an elevated prothrombin time or international 
normalised ratio, low albumin and low platelets. There are no 
autoantibodies diagnostic of PSC. Serum perinuclear antinuclear 
cytoplasmic antibody is positive in 33–88% of those with PSC 
but is not specific and is not related to disease activity or prog-
nosis.15 19–22
Similar to clinical outcomes in primary biliary cholangitis 
(PBC), recent data from retrospective studies support the use 
of falling ALP (normalisation or <1.5 x upper limit of normal 
(ULN)) as a stratifier for improved outcome in patients with 
PSC, independent of the therapeutic modality used23–25
There are contradictory data on whether a raised serum IgG4 
in patients with PSC (IgG4 + PSC) correlates with the disease 
course of PSC. In the study by Mendes,26 IgG4 + PSC was asso-
ciated with more aggressive disease and progression to transplan-
tation, but this was not seen in a European cohort of 345 patients 
with PSC.27 A further study including histological assessment of 
IgG4 staining in 98 liver explants from patients with a diagnosis 
of PSC, reported raised serum IgG4 levels in 22%, and raised 
tissue IgG4 levels in 23%.28 Again, those patients with raised 
IgG4 had a more rapid progression and need for liver trans-
plantation. It is uncertain whether these findings are explained 
by misdiagnosis in some cases (ie, cases of IgG4-SC incorrectly 
diagnosed as PSC), or whether they represent a more aggressive 
phenotype of PSC in those with elevated IgG4 levels. A further 
assessment of liver explants from patients with PSC undergoing 
transplantation reported at least moderate IgG4 immunostaining 
in 24.6% and was associated with higher rates of dominant stric-
tures, although this did not appear to correlate with age or speed 
of progression of disease.29
Some causes of secondary sclerosing cholangitis may respond 
well to medical treatment and it is therefore important to 
exclude secondary causes before making a diagnosis of PSC. 
Measurement of other biochemical tests, including antinuclear 
antibodies (ANA), antimitochondrial antibodies (AMA), smooth 
muscle antibodies (SMA), HIV antibodies, serum angiotensin 
converting enzyme, total immunoglobulins and immunoglob-
ulin subsets (including IgG4), should be performed and positive 
results should raise the suspicion of alternative diagnoses or 
overlap/variant syndromes.
Recommendation 1: There are multiple causes of cholan-
giopathy. We recommend that cholestatic liver biochemistry 
with typical cholangiographic features in the absence of other 
identifiable causes of secondary sclerosing cholangitis is usually 
sufficient for a diagnosis of PSC (strength of recommendation: 
STRONG; quality of evidence: MODERATE).
imaging
Transabdominal ultrasound scanning is rarely useful in the 
diagnosis of PSC, but may be helpful in excluding other causes 
of biliary obstruction such as choledocholithiasis, which can 
complicate stricturing disease and cholestasis in PSC. Ultrasound 
is also useful in the detection and surveillance of gallbladder 
polyps and in identifying developing portal hypertension. 
Contrast-enhanced CT may demonstrate features of cholangi-
opathy but is used primarily for the diagnosis and staging of 
suspected CCA.
Endoscopic retrograde cholangiopancreatography (ERCP) 
has been conventionally regarded as the 'gold standard' for 
the diagnosis of PSC, where the presence of a typical beading 
appearance caused by short multifocal strictures of the bile 
ducts is considered the best supportive evidence for the diag-
nosis of PSC. However, the risks involved with ERCP and 
improvement in image acquisition led to magnetic resonance 
cholangiopancreatography (MRCP) becoming the preferred 
imaging modality for the diagnosis of PSC. A number of 
studies have reported that the diagnostic accuracy of MRCP is 
comparable to that of ERCP, with a sensitivity and specificity 
of 80–100% and 89–100%, respectively.30–36 A meta-analysis 
of the diagnostic utility of MRCP included six well-controlled 
prospective studies and reported a sensitivity and specificity 
of 86% and 94%, respectively, for the diagnosis of PSC.37 
However, MRCP may be less sensitive than ERCP in detecting 
early changes of PSC and has less specificity in patients with 
cirrhosis.30 Contrast- enhanced MRI scanning may also provide 
additional information about liver parenchyma, presence of 
varices, CCA and lymphadenopathy.
Many of the studies describing and differentiating PSC from 
other diseases were done before the widespread recognition of 
IgG4-SC, which may be present in 20–88% of patients with 
IgG4-RD.38 Whereas some cholangiographic features, such 
as long biliary strictures with prestenotic dilatations, and low 
common bile duct strictures, are more suggestive of IgG4-SC, 
beading, peripheral duct pruning and pseudodiverticula point 
more towards PSC.39 Cholangiography alone is insufficient to 
distinguish IgG4-SC, PSC and CCA.40
Recommendation 2: We recommend that MRCP should be 
the principal imaging modality for the investigation of suspected 
PSC. ERCP should be reserved for patients with biliary strictures 
requiring tissue acquisition (eg, cytological brushings) or where 
therapeutic intervention is indicated (strength of recommenda-
tion: STRONG; quality of evidence: HIGH).
THE roLE oF LivEr biopsy
Modern imaging techniques have reduced the role of liver biopsy 
for diagnosis. A retrospective study of 138 patients with chol-
angiographic features of PSC concluded that liver biopsy rarely 
added diagnostic information in classic PSC.41 Liver biopsy 
should be considered when histopathology would help clarify 
diagnosis or alter management such as when there is a clinical 
suspicion of IgG4-SC, PSC overlap/variant syndromes and for 
diagnosis of small duct PSC. Liver biopsy may also help in other-
wise unexplained cholestasis.
The hallmark of PSC on histological assessment is concen-
tric ‘onion skin’ periductal fibrosis, but this is often not present 
on small liver biopsy specimens. Other features include bile 
duct proliferation, chronic periportal inflammatory change, 
cholangioectasia, ductopenia and varying degrees of fibrosis 
and cirrhosis.5 In practice, histological assessment is often 
non-specific, demonstrating general features of cholestasis. One 
 o
n
 19 June 2019 by guest. Protected by copyright.
http://gut.bmj.com/
G
ut: first published as 10.1136/gutjnl-2018-317993 on 1 June 2019. Downloaded from 
6 Chapman MH, et al. Gut 2019;0:1–23. doi:10.1136/gutjnl-2018-317993
Guidelines
recognised system describes four stages: (1) periportal inflamma-
tion, (2) periportal fibrosis, (3) ductopenia and bridging fibrosis 
and (4) cirrhosis.42
Recommendation 3: We recommend that liver biopsy is 
normally reserved for possible small duct PSC, assessment of 
suspected possible overlap variants or instances where the diag-
nosis is unclear (strength of recommendation: STRONG; quality 
of evidence: MODERATE).
non-invAsivE AssEssmEnT oF LivEr Fibrosis
While liver biopsy does provide information on the stage of 
liver fibrosis,43 there has been increasing interest in the value 
of non-invasive assessment in patients with PSC. One retrospec-
tive study highlighted the strong correlation between transient 
elastography and histological stage of liver fibrosis, as well as 
the prognostic significance.44 Serological assessment of liver 
fibrosis using the enhanced liver fibrosis test correlates with elas-
tography and helps to stratify prognosis in patients with PSC.45 
Both these modalities are undergoing further evaluation, and 
recent reports from a larger cohort suggest they may be effective 
markers of fibrosis and disease progression.46 Magnetic reso-
nance elastography is also emerging as a possible non-invasive 
marker of cirrhosis in PSC.47 European Association for the Study 
of the Liver (EASL) clinical practice guidelines recommend the 
use of non-invasive markers for monitoring the degree of liver 
fibrosis, but evidence specifically related to patients with PSC is 
still evolving.
wHAT oTHEr CondiTions sHouLd bE ConsidErEd in 
THE diFFErEnTiAL diAGnosis oF psC?
The main differential diagnoses for PSC include causes of 
secondary sclerosing cholangitis listed in box 1.
ovErLAp syndromEs
psC with additional features of AiH
There is a reported 1.4–17% overlap of AIH in adults diagnosed 
with PSC.48–50 Conversely, a prospective study of MRCP and 
liver biopsy in 59 patients with AIH demonstrated features of 
PSC in 1.7%.51 These patients typically have cholangiographic 
features of PSC in combination with findings suggestive of AIH, 
including younger age, higher transaminases, elevated immuno-
globulins, positive ANA, SMA and/or liver/kidney microsomal 
antibodies and mixed histopathological changes with interface 
hepatitis as well as the typical biliary pathology of PSC.
Patients who fulfil the diagnostic criteria of AIH published 
by the International Autoimmune Hepatitis Group respond 
to treatment with steroids and have a better prognosis than 
classic PSC, but worse than non-overlap AIH.48 52 An AIH/PSC 
overlap syndrome is more common in children (where it may be 
labelled autoimmune sclerosing cholangitis (ASC)), with chol-
angiographic features of sclerosing cholangitis reported in up to 
49% of children with antibody-positive AIH.53 We recommend 
management of PSC with additional features of AIH according 
to the EASL guidelines on the management of AIH.54 The impor-
tance of identifying an AIH overlap syndrome is due to the 
potential therapeutic benefit of immunosuppression, and hence 
liver biopsy is recommended for those with significantly raised 
transaminases, immunoglobulins or positive AIH autoantibodies 
(ALT >5 x upper limit of normal (ULN), IgG >x2 ULN, posi-
tive ANA, SMA and/or liver/kidney microsomal antibodies).54 
Some patients with features of AIH overlap syndrome progress 
to a more typical PSC phenotype.55 In this situation, ongoing 
treatment with immune suppression may not be effective and 
patients may require repeat assessment with cholangiography 
and consideration of repeat biopsy.
other overlap syndromes
A PSC/PBC overlap syndrome has been reported in only small 
case series.56 57 This may reflect the diagnostic difficulty in those 
with small duct PSC where the classic cholangiographic features 
are absent and liver biopsy is often not diagnostic. AMAs are 
positive in <5% of cases of PSC.58
It is not clear whether IgG4-SC can be an overlap syndrome or 
if it represents a separate condition with similar clinical features. 
However, a subset of patients with a diagnosis of PSC do have 
elevated serum levels of IgG4 as discussed elsewhere in the 
guidelines26 59
what other conditions may be associated with psC
psC in inflammatory bowel disease
Abnormal liver biochemistry is common in patients with IBD. 
In a cohort of 544 patients with IBD, 29% had at least one 
abnormal liver biochemical test, but only 5.8% had a clinical 
diagnosis of chronic liver disease (biopsy was not required for 
diagnosis in this series). When performed in a subset with a 
suspicion of biliary disease, cholangiographic features of PSC 
were present in 4.6% of all patients.60 In a recent study, 7.5% 
of patients with longstanding IBD (over 20 years' duration) with 
normal liver biochemistry, had evidence of cholangiopathy (9% 
of Crohn's disease, 6.8% ulcerative colitis), indicating that PSC 
may be underdiagnosed within cohorts of patients with IBD.61
IBD is present in 62–83% of patients with PSC of Northern 
European descent, but rates are as low as 21% elsewhere in the 
world.8 11 16 62–65 Patients often have extensive colitis, which may 
be of ulcerative colitis or Crohn’s colitis type. Rectal sparing 
and backwash ileitis are more common in IBD associated with 
PSC.66 PSC may be diagnosed before IBD but generally IBD is 
diagnosed some years before the identification of PSC. Despite 
potential mechanisms linking active colonic inflammation with 
the aetiology and activity of PSC, this has never been prop-
erly demonstrated. Clinically, the activity of IBD can follow an 
unpredictable course. Patients with PSC and IBD often describe 
minimal symptoms even in the presence of endoscopically and 
biopsy proven active IBD. Treatment of active colitis appears to 
have no impact on the progression of PSC.67 Case series also 
show that patients can develop changes of PSC years after colec-
tomy for ulcerative colitis. A number of small case series have 
described the pattern of IBD in PSC with and without liver 
transplantation and/or immunosuppression, demonstrating 
some cases of de novo presentation of IBD after transplantation 
or a paradoxical worsening of disease activity after liver trans-
plantation despite immunosuppression.68–70 Conversely, other 
transplant series report a milder course of IBD in those with 
more progressive PSC and/or improved IBD activity with immu-
nosuppression after liver transplantation.71 72 The reasons for 
these variable reports and patterns of disease are unknown but 
suggest that there is at most a weak correlation between activity 
of PSC and IBD. IBD appears to be rare in IgG4-SC, providing 
additional means to help distinguish this from IgG4 + PSC.
other associated conditions
PSC may rarely be associated with some other immune-mediated 
diseases, including coeliac disease, thyroid disease, Sjögren’s 
syndrome, type 1 diabetes mellitus, systemic sclerosis, retroper-
itoneal fibrosis, autoimmune haemolytic anaemia, sarcoidosis 
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and rheumatoid arthritis. An association with these conditions 
is uncommon and some may relate to IgG4-RD misdiagnosed as 
PSC (eg, when associated with retroperitoneal fibrosis).
what is the natural history of psC?
The natural history of PSC is variable and often unpredictable. 
Most patients are diagnosed in the fourth or fifth decades of life. 
The mean age of diagnosis is between 32 and 41 years.11 15 73 PSC 
is uncommon in childhood. Men are affected more commonly, 
with a male to female ratio of 2:1.
The mean time from diagnosis to death or liver transplantation 
is 10–22 years.8 12 15 73 74 It should be noted that most published 
data come from tertiary referral units and probably overesti-
mate the risk of complications and death. A population-based 
assessment of natural history in Holland demonstrated improved 
prognosis in the overall PSC population compared with those in 
liver transplant centres, with a median time from diagnosis to 
death or transplantation of 21 years and 13 years, respectively.12 
Asymptomatic patients are reported to have a better prognosis, 
but this is probably due in part to lead time bias with diagnosis 
at an early disease stage. Historically and before liver transplan-
tation, most patients died of complications of cirrhosis. In more 
recent series, most deaths are due to CCA (58%), liver failure 
(30%) and variceal bleeding (9%).15 Patients with small duct 
PSC appear to have a better prognosis and a very low risk of 
developing CCA, but a significant minority (23%) will develop 
cholangiographic features of classic PSC over time.75 76 Large 
retrospective series suggest that patients with PSC and Crohn’s 
disease have a better prognosis than those with ulcerative 
colitis.77
These studies have been reinforced by the recent International 
PSC Study Group (IPSCSG) cohort study of 7121 patients, of 
whom 2616 progressed to liver transplantation or death (median 
14.5 years); and 721 developed hepato-pancreato-biliary malig-
nancy, mainly CCA (n=594) (incidence rate: 5.4 and 1.4 per 
100 patient-years, respectively). Of these patients, 65.5% were 
men, 89.8% had classic/large duct disease and 70.0% IBD.78
prognostic scoring systems
It is difficult to predict the rate of progression or outcome for 
individual patients with PSC. Asymptomatic patients are likely to 
have a better prognosis than those with symptoms. Multivariate 
analyses in a number of series demonstrate clinically predictable 
parameters as being markers of poor prognosis. Some groups 
have devised prognostic models (summarised in table 1) using a 
variety of parameters, including age, blood results, liver biopsy 
staging, cholangiographic findings and complications such as 
a history of variceal bleeding.15–17 74 The most widely used is 
the revised Mayo natural history model for PSC. As with other 
models it has a complex formula reflecting the variability and 
complexity of the natural history of PSC. These models probably 
have little role for ordinary patient care and are rarely used in 
clinical practice in the UK. Their main roles are to assist in the 
timing of liver transplantation and for research studies. Model 
for End Stage Liver Disease (MELD) and UK Model for End 
Stage Liver Disease (UKELD) scores may be applied to patients 
with PSC as for patients with other causes of liver disease, but 
both may fluctuate highly and overestimate the stage of liver 
disease in view of the impact of biliary obstruction on the bili-
rubin component of the scores. The Child-Pugh score has been 
applied specifically to PSC, with 7-year survival rates of 90%, 
68% and 25% for scores A, B and C, respectively.79 Prognostic 
models using clinical and laboratory parameters for established 
PSC do not vary widely from data using the simple Child-Pugh 
score.
Recommendation 4: We recommend risk stratification based 
on non-invasive assessment. Clinical scores are an emerging 
theme but no single method can be recommended at present 
to predict individual patient prognosis. Given the unpredict-
able disease course and the serious nature of the complications 
of PSC, patients should receive lifelong follow-up (strength of 
recommendation: STRONG; quality of evidence: VERY LOW)
sclerosing cholangitis in children
Raised ALP is normal in growing children and adolescents, and 
is unreliable for screening for PSC. Abnormal liver biochem-
istry in children with IBD is common but most is thought not 
to be related to PSC. In a cohort of 300 children with IBD, scle-
rosing cholangitis was reported in 6%, with a persistently raised 
γ-glutamyl transpeptidase being the most predictive marker.80 
The proportion of children with abnormal liver biochemistry 
who develop features suggestive of PSC is not well reported. 
A prospective study of 55 consecutive children presenting with 
abnormal liver biochemistry and positive autoantibodies suggests 
that the distinction between classical PSC and AIH is much less 
clear in the paediatric population.53 Half of these children with 
Table 1 Comparison of published primary sclerosing cholangitis prognostic scoring systems
wiesner
1989
Farrant
1991
mayo score
1992
broome
1996
revised mayo 
score
2000
ponsioen
2002
Goode
2015
Age ✔ ✔ ✔ ✔ ✔ ✔ ✔
Bilirubin ✔ ✔ ✔ ✔
Albumin ✔
AST ✔
ALP ✔ ✔
Hb ✔
IBD ✔
Histology ✔ ✔ ✔ ✔
Splenomegaly ✔
Variceal bleed ✔
Cholangiogram ✔ ✔
Outcome Death Transplant Transplant Death/OLT Survival Survival Death/OLT
ALP, alkaline phosphatase; AST, aspartate aminotransferase; IBD, inflammatory bowel disease; OLT, orthotopic liver transplantation.
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AIH also had changes of sclerosing cholangitis at cholangiog-
raphy. Most had features of an overlap syndrome with positive 
autoantibodies, elevated transaminases, elevated immunoglob-
ulins and mixed histological findings of interface hepatitis and 
portal inflammation. The disease tends to progress to a more 
classic PSC pattern and become resistant to immunosuppressive 
treatment in the adult years. Classic PSC has also been described 
in children but appears to be rare. Some have therefore suggested 
that PSC is a ‘sequential syndrome’ or long-term consequence 
of damage from childhood AIH.81 The term autoimmune scle-
rosing cholangitis (ASC) has been used in children, but whether 
this is an early phase and/or the same condition as adult PSC 
remains unclear. MRCP is recommended in children with AIH 
that responds poorly to medical treatment in order to screen for 
changes of sclerosing cholangitis.
Children often require liver transplantation at a young age 
and have a high rate of disease recurrence in the graft.82 Chil-
dren with classic PSC have a disease pattern mirroring that of 
adults with a poor response to treatment and a median survival 
before developing significant events or transplantation of 10–12 
years.83 84 The outcome of classic PSC in children is worse than 
for children with steroid-responsive AIH or ASC, resulting in 
shorter transplant-free survival (78% at 5 years compared with 
87–90% for AIH/ASC).85
Adolescents with PSC should, where possible, be managed in 
transition clinics before long-term management in adult clinics.
How sHouLd pATiEnTs wiTH psC bE mAnAGEd?
drug therapies
Ursodeoxycholic acid (UDCA)
UDCA is a hydrophilic bile salt used to treat cholestatic liver 
diseases, including PBC. Retrospective observational studies 
from centres with high UDCA use demonstrated worse actu-
arial survival in comparison with predicted survival using PSC 
prognostic models, suggesting a lack of therapeutic benefit 
from UDCA.15 A number of randomised controlled trials have 
been performed, but these have been generally small (n=6–
110 patients) with a short follow-up of usually 12–24 months 
(range 12–60 months) and hence underpowered for identi-
fication of clinical events.86–92 Overall, the early studies using 
low doses of 10–15 mg/kg demonstrated improvement in liver 
biochemistry but not of liver histology and none have shown 
improvement in outcome measured by death or transplantation. 
Three small pilot trials of higher doses (20–30 mg/kg) have been 
published.88 93 94 All resulted in improvement of liver biochem-
istry and two included liver biopsy in the final clinical evalu-
ation. One of these showed a non-significant improvement in 
histological score in the high dose (30 mg/kg) group (n=9) and 
the other (n=21) demonstrated improvement in Ishak staging 
in 3 out of 11 patients (p=0.05) and cholangiographic findings 
(p=0.015) in two patients at 2 years. None showed improved 
outcome, but these pilot studies were not sufficiently powered 
to demonstrate a survival benefit.
In a large, but still underpowered study of 219 patients 
randomised to moderate dose UDCA (17–23 mg/kg) or placebo 
for 5 years,95 there was no significant difference in outcomes 
between the two groups, including symptoms, liver biochem-
istry, CCA, death or transplantation, although there was a trend 
towards reduction in mortality or transplantation in the UDCA 
group (7.2% vs 10.9%, p=0.4). Liver biopsy was not included 
in the protocol. A further, large, multicentre study of high-dose 
UDCA (28–30 mg/kg) in 150 patients with PSC was terminated 
early after results showed higher rates of serious adverse events 
and primary endpoints of death, liver transplantation and devel-
opment of varices in the UDCA-treated group.96 Meta-analyses 
of published data report no benefit from UDCA in patients with 
PSC.97 98 One uncontrolled study examined the effect of stop-
ping UDCA in patients already established on treatment and 
demonstrated worsening of liver biochemistry and pruritus after 
stopping treatment, but the study was not able to assess the effect 
on longer-term outcomes.99
In small duct PSC, small case series suggest that UDCA 
improves liver biochemistry but has no effect on development 
of complications, progression to classic large duct PSC or risk of 
death or transplantation.76 100
Overall it appears that UDCA improves liver biochemistry, 
but there is no evidence that it improves outcome and may be 
harmful in high doses.
Recommendation 5: We recommend that UDCA is not used 
for the routine treatment of newly diagnosed PSC (strength of 
recommendation: STRONG; quality of evidence: GOOD). For 
patients already established on UDCA therapy, there may be 
evidence of harm in patients taking high dose UDCA 28–30 mg/
kg/day (strength of recommendation: WEAK; quality of evidence: 
LOW).
Does ursodeoxycholic acid reduce cancer risk in PSC?
Early evidence suggested that patients with PSC treated with 
UDCA had a lower incidence of colorectal cancer than untreated 
patients. A retrospective study of 52 patients treated with UDCA 
for PSC followed up for >10 years showed a significant reduc-
tion in the incidence of colonic dysplasia or colorectal cancer 
(10% vs 35%).101 A second, cross-sectional study, reported the 
prevalence of colonic dysplasia or malignancy in 59 patients 
with PSC undergoing surveillance colonoscopy. A comparison 
of those treated or not treated with UDCA suggested a signif-
icant protective effect of UDCA on risk of colonic dysplasia 
or colorectal cancer (OR=0.14, 95% CI 0.03 to 0.64).102 
However, a further retrospective study reported no difference 
in the rate of colorectal cancer or dysplasia in those treated with 
UDCA (n=28) compared with PSC controls not using UDCA 
(n=92).103 A randomised controlled trial of 1285 patients 
(without PSC) undergoing surveillance colonoscopy following 
polypectomy showed a significant reduction in the risk of high-
grade dysplasia in recurrent adenomas in those patients treated 
with UDCA (OR=0.61, p=0.03). However, the overall inci-
dence of new adenomas was not statistically different (p=0.31) 
between UDCA treated (41%) or untreated groups (44%).104 
A randomised controlled trial (n=98) of UDCA (17–23 mg/kg) 
for the treatment of PSC reviewed the incidence of colorectal 
neoplasia as a secondary endpoint at almost 5 and 15 years. 
The rates of neoplasia were high but no difference was seen 
between the UDCA treated and untreated groups at either 5 
years (13% and 16%) or 15 years (27% and 30%).105 One study 
reported a higher rate of colorectal cancer associated with the 
use of UDCA106 Two meta-analyses report no significant effect 
of UDCA on rates of colorectal neoplasia in patients with PSC, 
although there was a trend towards lower rates of neoplasia in 
patients taking low-dose UDCA.107 108
There is little evidence for a beneficial effect of UDCA in 
reducing the risk of CCA, with no placebo controlled trials 
specifically examining this question. Two observational studies 
reported a lower incidence of CCA in patients taking UDCA 
in comparison with previously reported incidence rates.109 110 
The largest of these studies followed up 150 patients for a median 
of 6.4 years, with CCA developing in five patients (3.3%), which 
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represents about half the expected incidence of CCA in PSC. The 
large US randomised control trial of UDCA versus placebo was 
terminated early, but also failed to show a significant difference 
in the rate of either CCA (2.6% vs 2.7%) or colonic dysplasia in 
either the UDCA or placebo arms, respectively, at 5 years.96
Recommendation 6: We recommend that UDCA is not used 
for the prevention of colorectal cancer or cholangiocarcinoma 
(strength of recommendation: STRONG; quality of evidence: 
HIGH).
Immunosuppression and other treatments
Despite the presumed immune-mediated disease process in PSC, 
clinical experience of treating those with active colitis using 
steroids and other immunosuppressant agents has not demon-
strated improvement in PSC disease activity or outcome. Small 
randomised trials have investigated the role of prednisolone, 
budesonide, colchicine, penicillamine, azathioprine, ciclosporin, 
methotrexate, mycophenolate and anti-tumour necrosis factor 
monoclonal antibodies. There is no evidence that any of these 
drugs are effective and therefore none can be recommended for 
the treatment of classic PSC.111 112 Nevertheless, some of these 
drugs may have a role in an overlap syndrome, since paediatric 
patients and those with additional features of AIH are more 
likely to respond to immunosuppressive treatments.50 A retro-
spective study in adults suggested a beneficial role of steroids 
in a subgroup with additional features of AIH.113 Those with 
good evidence of PSC and additional features of AIH should be 
treated similarly to those with classic AIH.114 The choice of the 
most appropriate systemic steroid therapy is not clear.
Steroids have been given to the subset of patients with PSC 
and a raised serum IgG4 (after exclusion of IgG4-SC). In a 
small study of 18 patients, steroids led to a fall in bilirubin in 
9/10 patients with raised bilirubin, and a significant fall in ALP, 
but steroid-related side effects and post-steroid relapse were 
common.59
A review of small case series with limited evidence suggests 
modest improvement in liver biochemistry in patients treated 
with vancomycin.115 These data may justify a larger clinical trial 
but currently do not support the use of vancomycin (or other 
antibiotics) for treatment of PSC liver disease in the absence of 
cholangitis.
Recommendation 7: We recommend that corticosteroids and 
immunosuppressants are not indicated for the treatment of 
classic PSC (strength of recommendation: STRONG; quality of 
evidence: HIGH). In those patients with additional features of 
AIH or IgG4-SC, corticosteroids may be indicated (strength of 
recommendation: STRONG; quality of evidence: MODERATE).
roLE oF EndosCopy, ErCp And EndoTHErApy
Joint European Society of Gastrointestinal Endoscopy (ESGE) 
and EASL guidelines on the role of endoscopy in patients with 
PSC have recently been published and should be reviewed along 
with these guidelines4
Oesophageal and gastric varices have been reported in 7–36% 
of patients with PSC.15 116 Screening and appropriate treat-
ment of varices should be considered in those with evidence of 
cirrhosis and/or portal hypertension, such as those with throm-
bocytopenia, jaundice and an elevated AST/ALT ratio or those 
with evidence of cirrhosis on elastography or imaging.116 117
Colitis is common in patients with PSC and patients may have 
few or no symptoms. A full colonoscopy with colonic biopsies 
is therefore strongly recommended after a diagnosis of PSC in 
order to identify occult IBD, and to determine the need for colo-
noscopic surveillance of colorectal neoplasia.
ERCP has historically been the preferred investigation for 
suspected PSC, but carries significant risks. One retrospective 
study of almost 9000 ERCPs, including 141 patients with PSC, 
reported higher rates of pancreatitis (7.8%), cholangitis (7.1%) 
and overall complications (18%) in patients with PSC compared 
with other indications.118 However, other large series reported 
a relatively low complication rate of 4.3% from ERCP in 
patients with PSC (pancreatitis 1.2%, cholangitis 2.4%, bleeding 
0.7%).119 Patients with PSC should ordinarily not undergo 
ERCP until there has been expert clinico-radiological assessment 
to justify endoscopic intervention.
In PSC, after ERCP, cholangitis rates of up to 36% are 
reported in case series.120 121 National Institute for Health and 
Care Excellence (NICE) and BSG guidelines advise that prophy-
lactic antibiotics are required if complete biliary drainage at 
ERCP is unlikely to be, or is not, achieved. PSC with intrahe-
patic and/or extrahepatic stricturing is considered such a situ-
ation and so prophylactic antibiotics should be used for ERCP 
in patients with PSC.122 The recommended antibiotic regimens 
vary according to local policies but commonly include co-amox-
iclav, quinolones, gentamicin or cephalosporins for 3–5 days. 
There is no role for the addition of antibiotics to contrast agents 
used during ERCP.123
Recommendation 8: We recommend that endoscopic 
screening for oesophageal varices should be done in line with 
international guidelines where there is evidence of cirrhosis and/
or portal hypertension (strength of recommendation: STRONG; 
quality of evidence: HIGH).
Recommendation 9: We recommend that colitis should be 
sought in all patients with PSC using colonoscopy and colonic 
biopsies (strength of recommendation: STRONG; quality of 
evidence: MODERATE).
Recommendation 10: We recommend that patients with 
suspected PSC undergoing ERCP should receive prophylactic 
antibiotics (strength of recommendation: STRONG; quality of 
evidence: MODERATE).
dominant bile duct strictures
It is important that in patients presenting with signs of biliary 
obstruction and/or those who develop changing symptoms or 
evolving abnormalities in laboratory investigations, non-invasive 
investigations such as MRCP, dynamic liver MRI and/or contrast 
CT should be performed and reviewed by a hepatopancreati-
cobiliary (HPB) MDT before any high-risk invasive endoscopic 
interventions.
A dominant stricture is often not simple to define in clinical 
practice but a pragmatic definition is of functional stenoses of 
the major bile ducts with signs of biliary obstruction shown by 
worsening liver biochemistry and/or proximal biliary dilatation 
or symptoms of cholestasis. The prevalence of dominant bile 
duct strictures in PSC is 36–50%.15 121 124 125 Patients with domi-
nant strictures have significantly worse outcomes than those 
without, even when regular endoscopic treatment of stenoses is 
applied and CCA is excluded.125
Decision-making about intervention for dominant strictures 
is important but complex. A common consensus has been that 
patients with PSC who do not have significant jaundice and/or 
have not had episodes of cholangitis in the presence of assumed 
functionally significant extrahepatic strictures should avoid 
ERCP unless a clinical suspicion of CCA based on non-invasive 
imaging is high.
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Differentiating benign from malignant causes of dominant 
strictures is crucial but difficult. Biliary brush cytology is the 
standard investigation for suspicious biliary strictures but despite 
excellent specificity, its sensitivity is poor. A systematic review of 
the published literature (n=747) on the use of biliary brushings 
in the diagnosis of CCA in PSC reported a sensitivity of 43% 
and specificity of 97%.126 The sensitivity of cytology from bile 
aspirates is lower. A single-centre prospective study of system-
atic biliary brushings at index ERCP in 261 patients with PSC 
reported malignancy or dysplasia suspicious for malignancy in 
7%.127 Additional cases of biliary dysplasia were identified in 
explants of patients who underwent transplantation. Some inter-
national centres use dysplasia in brushings as a marker of in situ 
carcinoma and refer these patients for consideration for liver 
transplantation.127 128 However, CCA remains a contraindication 
to liver transplantation in the UK. Other markers using fluores-
cence in situ hybridisation (FISH) analysis in biliary brushings 
or KRAS and p53 in bile have been evaluated, but are not suffi-
ciently sensitive or specific to be useful as screening or diagnostic 
tests.129–132 A meta-analysis of 828 patients with PSC undergoing 
assessment by FISH demonstrated sensitivity and specificity of 
68% and 70%, respectively.133 Other approaches such as using a 
panel of biomarkers may show more promise in the future.
Another approach to tissue diagnosis at ERCP is fluoroscop-
ically guided intraductal biopsy without direct cholangioscopy. 
Selected studies (not PSC specific) demonstrate relatively high 
rates of tissue confirmation of malignancy (70%) using larger 
biopsy forceps.134 Rates for confirmatory tissue diagnosis can be 
improved by multimodal sampling using brushings, biopsy and 
EUS.135 Similarly, the use of multiple crushed biopsy specimens 
analysed immediately by a pathologist during the ERCP proce-
dure may improve diagnosis rates.136
Intraductal cholangioscopy can aid the diagnosis of indetermi-
nate biliary strictures. Early case series, including patients with 
PSC, suggested that very high sensitivities (92–100%) could be 
achieved for the diagnosis of malignant biliary strictures using 
direct visualisation without biopsy, although with a decline in 
specificity to 87–93%.137 138 Larger, more recent studies using 
video cholangioscopy and multicentre registries have reported 
high sensitivities (62–99%) and specificities (64–100%) for the 
diagnosis of biliary strictures.139–143 A UK multicentre experience 
of cholangioscopy for the diagnosis of CCA in PSC and IgG4- 
related cholangitis suggests that in comparison with investigation 
of possible CCA in patients without cholangiopathy, it is similarly 
efficacious (sensitivity 50%).144 Technological developments and 
the wider availability of cholangioscopy will probably lead to an 
increasing role for this procedure in the assessment of strictures 
in PSC.145 Early studies on the addition of adjunctive techniques 
to EUS and cholangioscopy, such as intraductal chromoendos-
copy, narrow band imaging and confocal laser microscopy, are 
emerging.139 146–148 These techniques are limited to specialist 
centres, but availability is expanding.
Endotherapy of dominant bile duct strictures
The exact role of endoscopic therapy in the management of 
dominant strictures in PSC remains incompletely understood. 
Investigations in animals and humans suggest that decompression 
of biliary obstruction prevents further damage and can reverse 
fibrotic liver disease.149 This is supported by data demonstrating 
that patients with PSC who achieve normalisation or near 
normalisation of ALP have improved outcomes compared with 
those who do not.24 25 It is clear that endoscopic treatment of 
biliary strictures often improves liver biochemistry and pruritus, 
and may reduce the risk of recurrent cholangitis. Consensus has 
been for repeated endoscopic intervention (usually stricture dila-
tation ± stenting) of dominant biliary strictures in those with 
symptomatic disease.150–152 Evidence from studies comparing 
jaundice, cholangitis, transplantation and actuarial survival rates 
with figures from prognostic models, tend to suggest a benefit of 
endoscopic intervention for dominant biliary strictures.124 153–155 
In contrast, a Swedish study comparing liver biochemistry in 
those with and without dominant strictures suggested that varia-
tions in cholestasis and jaundice are a feature of PSC liver disease 
and are not a direct consequence of endotherapy of dominant 
strictures.121
The optimum method and frequency of dilatation of dominant 
strictures is unclear. Plastic stent insertion with or without prior 
stricture dilatation has been commonly used. The difficulty with 
this approach is that further ERCPs are required to remove or 
replace the stent and there is a high rate of stent occlusion and/
or cholangitis within 3 months of insertion. One uncontrolled 
study of short-term stenting (mean 9 days) reported improved 
outcome, particularly for resolution of jaundice and symptoms 
of cholestasis (81% compared with 57% in historical controls 
undergoing 2–3 monthly elective stent changes).155 Other studies 
have compared the role of stenting with balloon dilatation, with 
similar efficacy and lower rates of complications such as cholan-
gitis associated with balloon dilatation alone (18% vs 50%).156 
Multiple dilatations are usually required over months or years in 
order to maintain patency once dominant strictures are identi-
fied. A large (n=171) uncontrolled prospective study of patients 
with PSC included 96 patients with dominant strictures under-
going regular balloon dilatations over a median follow-up of 7 
years.157 Over 500 dilatations were performed (only five stents 
inserted) with low complication rates of 2.2% for pancreatitis, 
1.4% for cholangitis and 0.2% for bile duct perforation, and 
5- and 10-year transplant free survival rates of 81% and 52%, 
respectively.
Balloon dilatation in preference to stenting has been advised 
in European and American guidelines on the management of 
patients with PSC.1 2 4 Some strictures do not open satisfacto-
rily with balloon dilatation alone and stent insertion is usually 
recommended in these cases. A meta-analysis in other benign 
causes of biliary stricture and/or obstruction, shows that inser-
tion of multiple plastic stents offers higher rates of relief of 
cholestasis (94% vs 60%) and lower complication (mostly chol-
angitis) rates (20% vs 36%) than single stent insertion.158 In a 
multicentre randomised trial of patients with PSC and a domi-
nant stricture (n=65), short-term stents were not superior to 
balloon dilatation and were associated with significantly higher 
complications of pancreatitis and cholangitis in the stent group 
(45%) than in the balloon dilatation group (7%)159
Fully covered self-expandable metal stents are now well estab-
lished in the management of benign biliary strictures of different 
aetiologies.160 161 Case series including small numbers of patients 
with PSC also suggest a role for these stents in dominant stric-
tures below the liver hilum due to PSC.161–163
Some strictures are not amenable to, or do not require, endo-
scopic intervention. In these patients, careful consideration 
should be made about a conservative, radiological or surgical 
(including liver transplantation) approach to treatment before 
ERCP is performed. If ERCP is performed in the presence of 
dominant stricture, it is important that consideration is made 
of possible CCA and that appropriate sampling is undertaken if 
there is any clinical suspicion of malignancy.
Recommendation 11: We recommend that non-invasive inves-
tigations such as MRCP, dynamic liver MRI and/or contrast CT 
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should be performed in patients who have new or changing 
symptoms or evolving abnormalities in laboratory investigations 
(strength of recommendation: STRONG; quality of evidence: 
MODERATE).
Recommendation 12: We recommend that patients with PSC 
should ordinarily not undergo ERCP until there has been expert 
multidisciplinary assessment to justify endoscopic intervention 
(strength of recommendation: STRONG; quality of evidence: 
MODERATE).
Recommendation 13: We recommend that in patients under-
going ERCP for dominant strictures, pathological sampling of 
suspicious strictures is mandatory (strength of recommendation: 
STRONG; quality of evidence: STRONG).
Recommendation 14: We recommend that in patients 
undergoing ERCP for dominant strictures, biliary dilatation is 
preferred to the insertion of biliary stents (strength of recommen-
dation: STRONG; quality of evidence: MODERATE).
spECiALisT rEFErrAL
We suggest that care provision should involve a partnership 
between patients, primary care and hospital-led specialty medi-
cine. Care delivery for an individual patient should encompass 
patient risk assessment, symptom burden and how local services 
are configured. All patients should have at least an annual review, 
which should become more frequent as required if symptoms 
or complications develop. The timing of referral to specialist 
regional HPB units will vary and depend on physicians’ experi-
ence in caring for patients with PSC, and in biliary intervention. 
In practice, referral will be at the point where a patient’s clinical 
management is beyond both the local expertise and knowledge of 
their responsible physician and team. As a general rule, all symp-
tomatic patients should be under the care of a specialist clinician 
or HPB centre with an interest and experience in managing PSC. 
In the absence of effective medical treatment and with the unpre-
dictable natural history of PSC, it is important that patients are 
referred early for consideration of liver transplantation. Patients 
with jaundice from suspected parenchymal disease, rising liver 
disease scores (MELD >11, UKELD >46) or complicated biliary 
strictures, require discussion with specialist units for consider-
ation of endoscopic, radiological and/or surgical biliary interven-
tion or liver transplantation. Other reasons to consider referral 
include persistently raised ALP levels,23 transient elastography 
of >9.9 kPa44 or an enhanced liver fibrosis test result of >10.6.45 
Patients with early, asymptomatic, stable disease can usually be 
managed by non-specialist gastroenterologists or other clini-
cians with adherence to management guidelines. Centres with a 
particular interest in PSC may be undertaking clinical trials, and 
patients should be offered the chance to enter into such trials. 
All patients with suspected CCA or other malignancies should 
be referred to the appropriate regional multidisciplinary cancer 
meeting for review.
Recommendation 15: We suggest that provision of care should 
involve a partnership between patients, primary care and hospi-
tal-led specialty medicine with consideration made with regard to 
patient risk assessment, symptom burden and how local services 
are configured (strength of recommendation: WEAK; quality of 
evidence: LOW).
Recommendation 16: We recommend that patients with 
symptomatic, evolving or complex disease should be referred for 
expert multidisciplinary assessment. Patients with early, stable 
disease can be managed in general clinics (strength of recommen-
dation: STRONG; quality of evidence: LOW).
Recommendation 17: We suggest that patients with PSC 
meeting inclusion criteria should be offered referral to a centre 
participating in clinical trials (strength of recommendation: 
WEAK; quality of evidence: LOW).
LivEr TrAnspLAnTATion
Advanced liver disease secondary to PSC is a well-established 
indication for liver transplantation.164 165 Patients receiving a 
transplant owing to PSC have excellent outcomes compared 
with many other indications. The European Liver Transplant 
Registry (which includes the UK data) has recorded 1-, 3- and 
5-year survival rates of 86%, 80% and 77%, respectively, in 
patients transplanted between 1988 and 2005. Data from the 
US registries of more recent cases indicate even better survival, 
although the results for PSC are poorer than for PBC, even 
though patients with PSC were younger.166 The optimal timing 
of referral for transplant assessment is difficult because jaun-
dice can be caused by both liver failure and/or biliary obstruc-
tion, which may respond to endoscopic therapy. Owing to the 
difficulties in predicting outcome and the particular risks of 
severe recurrent cholangitis and CCA, in some national alloca-
tions schemes, patients with PSC are given exemption points to 
balance their risk compared with other causes of cirrhosis when 
using scoring systems such as MELD. Some have advocated early 
transplantation in PSC because of the risk of CCA, but the risk 
of recurrent PSC in the graft and long-term survival data being 
poorer than a conservative approach in early disease do not 
favour this opinion.166
A large study analysing the American transplant United 
Network for Organ Sharing (UNOS) database reported a lower 
death rate for patients with PSC on the waiting list (13.6%) than 
for other indications (20.5%).167 A variable potentially skewing 
these data is the higher rate of living donor transplants in the 
PSC population, resulting in dropout from the standard waiting 
list.167 The most common cause of death for patients with PSC 
on a transplant waiting list is development of cholangiocarci-
noma. Complications of portal hypertension are much lower 
than for other listing indications, which has been proposed as 
the reason that patients with PSC on the waiting list have a more 
favourable outlook than patients with other indications.167 168 
Furthermore, bacterial cholangitis does not appear to be asso-
ciated with an increased risk of waiting list removal for death 
or clinical deterioration, calling into question the rationale for 
granting additional exemption points for this indication.169
In general, patients with PSC should be referred early for 
consideration of transplantation if there is cirrhosis and/or 
portal hypertension associated with any complications or when 
the UKELD or MELD scores rise towards minimal listing criteria 
(currently 49 and 15, respectively).170 171 The presence of intrac-
table pruritus (uncommon in PSC) and recurrent cholangitis are 
also accepted indications for orthotopic liver transplant within 
the UK and should justify earlier referral for consideration of 
liver transplantation (http:// odt. nhs. uk/ pdf/ liver_ selection_ 
policy. pdf).
Recurrence of PSC in transplanted livers is seen in 10–40% 
of cases.165 172–177 The main identifiable risk factors for recur-
rent disease are male sex, the presence of an intact colon and/or 
active colitis after transplantation.174–176 178 There is no evidence 
that post-transplant immunosuppression with single or multiple 
agents reduces the risk of recurrent disease, although most units 
favour a triple immunosuppression regimen. Diagnosis of recur-
rence is based primarily on clinical findings of typical cholangi-
opathy (either by radiographic or liver biopsy assessment) after 
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90 days in the absence of other causes, including hepatic artery 
ischaemia, ABO incompatibility and established ductopenic 
rejection. Recurrent disease can be difficult to treat and neces-
sitates retransplantation in approximately 50% of cases. Duct 
to duct biliary anastomosis should be undertaken whenever 
possible as it is associated with a reduced risk of cholangitis.179 
Anastomotic or de novo dominant strictures are usually managed 
with balloon dilatation and/or biliary stent insertion (plastic or 
possibly removable fully covered metal stents) but occasionally 
require surgical repair.
As for other immune-mediated liver diseases including AIH 
and PBC, there is a higher frequency of acute and chronic rejec-
tion, with reported rates of early acute rejection between 39% 
and 71%.165 176 In a retrospective series of over 3000 patients 
included in the American UNOS database and a smaller UK 
series166 174 graft dysfunction in PSC, from whichever cause 
resulted in a retransplantation rate of 12.4– 13.5%.
Other subjects relevant to transplantation include complica-
tions of coexisting IBD which can make surgery more complex, 
the need for annual surveillance for colorectal cancer (predicted 
colorectal cancer incidence of 1% a year associated with PSC 
and long-term immunosuppression) and the higher rate of recur-
rent disease in those with IBD.176 180 For these reasons, some 
centres have advocated colectomy at the time of liver transplan-
tation, but this remains contentious in the absence of colonic 
dysplasia or difficult to control colitis before transplantation. 
Patients with IBD being considered for transplantation should 
stop smoking and their IBD should be in remission by the time 
of transplantation as both these measures improve the outcome 
from liver transplantation.181
Recommendation 18: PSC is a well-recognised indication for 
liver transplantation. We recommend that eligibility and referral 
should be assessed in line with the national guidelines (strength 
of recommendation: STRONG; quality of evidence: HIGH).
How do i mAnAGE CompLiCATions oF psC?
Cholangitis
Cholangitis is a common complication of PSC. Bacterobilia is 
reported in 55% of patients at the time of liver transplanta-
tion, increasing to at least 77% in those who have predisposing 
factors such as biliary strictures or previous biliary instrumen-
tation.182 Cholangitis can present without significant change in 
baseline liver biochemistry as infections can be limited to small 
liver segments. A clear risk factor for cholangitis or positive bile 
cultures is previous ERCP with or without therapeutic interven-
tion, with the highest risk seen when stents are left in situ. A 
study (not in PSC) reported a positive bile culture rate of 98% 
in those with a stent in situ and 55% in those without.183 The 
number and variety of bacterial isolates were inversely propor-
tional to the time since the last ERCP.182 Another potential source 
of cholangitis is portal bacteraemia, which has been described in 
patients with active colitis.184 ERCP is a risk major factor for 
cholangitis in PSC and antibiotics should be routinely used as 
recommended above.
Biliary infections are often polymicrobial, but the most 
common organisms are Eschericia coli, Klebsiella, Entero-
coccus, Clostridium, Steptococcus, Pseudomonas and Bacteroides 
species.185 The choice of antibiotic agent should be directed by 
local practice after taking into consideration the history, severity 
of liver or renal disease and bacterial sensitivities. A common 
first-line agent for mild episodes is a fluoroquinolone such as 
ciprofloxacin. More severe cases are usually treated with intra-
venous cephalosporins or extended spectrum penicillins with 
the addition of anaerobic cover.185 186 Candida species have 
been isolated from the bile of 8/67 (12%) patients with PSC 
undergoing ERCP.187 However, the clinical relevance of fungal 
contamination of bile is unknown. Antifungal therapy should be 
considered in those with cholangitis not responding to antibiotic 
therapy.
Patients with severe acute cholangitis and dominant bile duct 
strictures require urgent biliary decompression, as the mortality 
in those untreated is high.186 In patients with recurrent cholan-
gitis secondary to complex intrahepatic cholangiopathy, rotation 
of antibiotics is occasionally used. This can lead to multiple anti-
biotic resistances and should be avoided where possible. Where 
this option is considered, expert multidisciplinary assessment, 
including formal microbiology advice, should be sought.
Cirrhosis, portal hypertension and liver failure
In an observational series of 174 patients with PSC who under-
went a liver biopsy, advanced fibrosis or cirrhosis was found in 
43% of patients with asymptomatic disease, and in 69% of those 
who were symptomatic64; 25% died of liver failure. Other studies 
have shown similar results.15 188 It is likely that these series are 
subject to referral bias with patients at a more advanced stage 
than many patients routinely followed up in local centres, but 
they indicate a high prevalence of advanced parenchymal liver 
disease in PSC. The true prevalence of portal hypertension is not 
known, but extrapolating data from clinical findings, such as the 
presence of splenomegaly and oesophageal varices, suggests that 
clinically significant portal hypertension is present in 30%.15 188
metabolic bone disease
As with other cholestatic liver diseases, osteopenia and osteo-
porosis are common in PSC.189 190 In a study of 237 patients 
who underwent annual measurement of bone mineral density, 
15% had evidence of osteoporosis, equating to a 24-fold risk of 
osteoporosis compared with an age-matched population.191 In 
this study, the presence of older age (>54 years), low body mass 
index (<24 kg/m2) and presence of IBD were strong risk factors 
of low bone density (prevalence of 75% with all three risk factors 
and 3% with none), but interestingly, cumulative dose of corti-
costeroids was not. Patients may also have coexistent vitamin D 
deficiency, but overt osteomalacia is uncommon. UK guidelines 
on the management of osteoporosis associated with chronic liver 
disease advise that all patients should receive lifestyle advice and 
those with cirrhosis or advanced cholestasis should have bone 
densitometry performed every 2 years.192 In practice, young 
patients with early disease are at low risk of low bone density 
and will not usually require formal testing. Patients with a high 
risk of bone disease and those requiring steroid treatment for 
IBD or liver transplantation should be treated with daily vitamin 
D 400 IU (10 μg) and calcium supplements if calculated dietary 
calcium intake is insufficient. Those with confirmed osteopo-
rosis should be treated according to BSG and NICE guidelines 
and fracture risk scores (http://www. nice. org. uk).192
Recommendation 19: We recommend that all patients with 
PSC should have a risk assessment for osteoporosis. Once osteo-
porosis is detected, treatment and follow-up should be in accor-
dance with national guidelines (strength of recommendation: 
STRONG; quality of evidence: MODERATE).
poor nutrition and fat soluble vitamin deficiency
Poor nutrition is common in chronic liver disease and should 
be considered and treated appropriately in patients with PSC. 
Advanced cholestasis can result in malabsorption of fat-soluble 
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vitamins. In advanced disease before transplantation, deficiency 
of vitamin A, D and E in 82%, 57% and 43%, respectively, are 
reported, but much lower levels of deficiency are seen earlier in 
the disease process.193 Evidence of deficiency of any measurable 
vitamin should lead to consideration of empirical replacement 
with multivitamins.
Recommendation 20: Poor nutrition and fat-soluble vitamin 
deficiency are relatively common in advanced PSC and we 
suggest that clinicians should have a low threshold for empir-
ical replacement (strength of recommendation: WEAK; quality of 
evidence: MODERATE).
Fatigue and depression
Fatigue is a common symptom of patients with chronic liver 
disease, but no treatments have been proved to be beneficial.194 
Depression is also common in people with chronic illnesses, and 
there are mixed reports of the association between depression 
and fatigue in PSC.194 195 One study directly assessing quality 
of life and fatigue scores in PSC, reported a lower incidence of 
fatigue than in the general population and when present, symp-
toms were associated with depression rather than severity of 
liver disease.194 There does not appear to be a role for the treat-
ment of fatigue using antidepressants without clear symptoms of 
depression.196–198
Recommendation 21: We recommend that in patients with 
fatigue, alternative causes should be actively sought and treated 
(strength of recommendation: STRONG; quality of evidence: 
LOW).
pruritus
Pruritus has a significant detrimental effect on quality of life for 
patients with PSC.199 The mechanism of pruritus in cholestasis 
remains unclear, which makes targeted treatment difficult. 
Antihistamines are not effective for the pruritus of cholestasis. 
There are few data for treatment in PSC and most recommen-
dations are extrapolated from trials in PBC.200 Pruritus associ-
ated with advanced disease is difficult to treat medically, and 
treatable biliary obstructions should be sought and relieved as 
above. The first line of medical treatment is usually cholestyr-
amine, colesevelam or colestipol. Care is needed to avoid admin-
istering soon before or after other medications. Further possible 
treatments include rifampicin and opiate antagonists such as 
naltrexone. The efficacy of these drugs is variable and they 
tend to have significant side effects. Patients with intractable 
pruritus not responsive to standard medical treatment should be 
offered referral to a specialist and/or transplant unit for further 
management.
Recommendation 22: We suggest that cholestyramine (or 
similar) is first-line medical treatment for pruritus. Rifampicin 
and naltrexone are second-line therapies (strength of recommen-
dation: WEAK; quality of evidence: LOW).
Cancer
Cholangiocarcinoma (CCA)
Malignancy, particularly CCA, is now the the most common 
cause of death in patients with PSC who have not undergone 
transplantation.201 The incidence of CCA in PSC is between 
0.6% and 1.5% a year, with a prevalence of 6–13% and a lifetime 
risk of up to 20%.15 62 64 125 188 202 203 Approximately half of cases 
of PSC-associated CCA are identified within a year of presen-
tation of PSC, and may be the reason for presentation of previ-
ously unrecognised PSC.125 203–205 There is no clear evidence that 
the risk of developing cancer is related to the duration of PSC 
disease. The incidence of CCA is highest in those with dominant 
strictures, with up to 76% located within the perihilar region.125 
CCA is rare in small duct PSC.75 76 203 206 A summary for manage-
ment of suspected cholangiocarcinoma is outlined in figure 2.
The usual modes of presentation are with upper abdominal 
pain, worsening liver biochemistry, jaundice and a raised serum 
CA19.9. CCA tends to spread by local invasion of the bile ducts 
and much less often with mass formation, so that cross-sec-
tional imaging may fail to identify the tumour. It is difficult to 
distinguish benign from malignant biliary strictures by MRCP or 
ERCP. Endoscopic assessment of suspicious biliary strictures is 
discussed above. Physicians should refer patients to units with 
experience in ERCP and EUS if there is continuing concern 
about biliary malignancy in patients with PSC.
Tumour markers used in clinical practice are CA19.9 and 
CEA but neither is sufficiently sensitive or specific for the 
diagnosis of CCA either alone or in combination.207–210 These 
studies used primarily CA19.9 with a cut-off point of 37–186 
kU/L. The sensitivity and specificity ranged between 50% and 
89% and 54% and 98%, respectively. The positive predictive 
value is low. The main problem with this marker is that it is 
frequently elevated in cholestasis and cholangitis, both of which 
are common in PSC. Another finding was that those with high 
levels of CA19.9 had unresectable disease, suggesting that it is 
not useful in surveillance.211 The utility of CA19.9 and various 
imaging modalities was reported in a large series of patients 
with PSC; no level of CA19.9 demonstrated reliable detection 
of CCA.212 Early retrospective data suggest that a rising trend 
in CA19.9 for individual patients may be more predictive than 
the actual level for the presence of early cholangiocarcinoma.213 
Therefore, CA19.9 may be useful for supportive evidence of 
CCA but is not reliable for screening or for confirmation of the 
diagnosis of CCA.
Early reports suggested positron emission tomography 
(PET) scanning may be useful for surveillance or investigation 
of suspected CCA.214 However, a further study of 36 patients 
(without PSC) with suspected CCA demonstrated a sensitivity 
of 85% for mass-forming tumours, 65% for metastases but only 
18% for infiltrating tumours.215 One small prospective study 
on the use of PET in transplant assessment (n=10, four with 
CCA) reported a sensitivity of 75% and false-positive rates of 
20% in the presence of cholangitis.216 Studies of PET scanning 
in sporadic CCA, demonstrate sensitivities of 61–92% and spec-
ificities of 75–93%.215 217 The detection rate falls to as low as 
36–59% in cases of extrahepatic disease with infiltrating rather 
than mass-forming disease.218 219 Therefore, PET is not routinely 
recommended for surveillance or diagnosis of CCA in PSC.
Cases of suspected CCA should be referred for review in the 
regional specialist hepatobiliary and pancreatic MDM or liver 
transplant centre. Decisions on treatment depend on the stage of 
disease. Chemotherapy remains the main palliative treatment for 
patients with CCA and will be directed by the specialist MDM. 
Although resectional surgery may be curative, this is usually not 
possible in patients with PSC (particularly with hilar/intrahepatic 
malignancy) because of either advanced stage malignancy at 
diagnosis, complex biliary structuring or coexistent parenchymal 
liver disease precluding a major liver resection. A retrospective 
multicentre study of 47 patients with liver transplantation for 
hilar CCA (not PSC specific) reported a high rate of recurrence 
(34%) and poor 5-year survival (22%).220 A Canadian study of 
patients who received a transplant for PSC reported an 80% 
recurrence rate, and a median time to recurrence of 26 months in 
10 patients with an incidental finding of CCA in the explant.221 
UK data demonstrate similar outcomes.222
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In the UK, CCA remains a contraindication to liver trans-
plantation after poor outcomes, with high rates of recur-
rence reported, even in cases of incidental CCA found in liver 
explants.171 However, in selected cases, 3-year survival rates of 
35–50% have been achieved.223 A series from the USA suggests 
that highly selected cases with early-stage hilar CCA have good 
outcomes when treated with preoperative chemotherapy and 
radiotherapy followed by transplantation.224 225 A more recent 
review of 287 patients in 12 US centres undergoing neoadju-
vant chemo-radiotherapy followed by transplantation for early 
CCA reported a 65% 5-year recurrence-free survival.226 Deci-
sions about transplantation when biliary dysplasia is identified at 
tissue sampling are complex and require in-depth discussions in 
a formal liver transplant MDM.
Recommendation 23: We suggest that an elevated CA19.9 
may support a diagnosis of suspected cholangiocarcinoma but 
has a low diagnostic accuracy. Routine measurement of serum 
CA19.9 is not recommended for surveillance for cholangiocar-
cinoma in PSC (strength of recommendation: WEAK; quality of 
evidence: MODERATE).
Recommendation 24: We recommend that when a diag-
nosis of cholangiocarcinoma is clinically suspected, referral for 
specialist MDM review is essential (strength of recommendation: 
STRONG; quality of evidence: MODERATE).
Recommendation 25: We recommend that where cholan-
giocarcinoma is suspected, contrast-enhanced, cross-sectional 
imaging remains the initial preferred investigation for diagnosis 
and staging (strength of recommendation: STRONG; quality of 
evidence: HIGH). Confirmatory diagnosis relies on histology 
with the approach to tissue sampling guided by MDM review. 
Options include ERCP-guided biliary brush cytology/FISH/ endo-
biliary biopsy/cholangioscopy/EUS-guided biopsy and/or percu-
taneous biopsy (strength of recommendation: STRONG; quality 
of evidence: HIGH).
other hepatopancreaticobiliary cancers
Gallbladder polyps are more often malignant in patients with 
PSC than in those without PSC, and malignancy may occur even 
in polyps <1 cm.227 228 A study of explanted livers from patients 
with PSC reported a high prevalence of dysplasia or cancer of 
the gallbladder, with 14% of resected gallbladders having foci 
of adenocarcinoma.229 No studies have been carried out exam-
ining prospective ultrasound surveillance of gallbladder polyps 
in patients with PSC. The US guidelines recommend cholecys-
tectomy when polyps are identified, but this should be balanced 
against the increased risk of surgery in patients with more 
advanced cirrhosis and portal hypertension.
Early reports suggested that hepatocellular carcinoma (HCC) 
has a prevalence of 2–4% in PSC.62 230 However, other reports 
suggest that the incidence of HCC in patients with PSC is 
extremely low, even in the presence of cirrhosis.231 Pancreatic 
cancer is reported to have a 14-fold standard incidence ratio 
compared with expected rates in the general population.62
Figure 2 Algorithm for the investigation of possible cholangiocarcinoma in patients with primary sclerosing cholangitis.
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Recommendation 26: We suggest that an annual ultrasound 
scan of the gallbladder should be performed in patients with 
PSC. If polyps are identified, treatment should be directed by 
specialist HPB MDM (strength of recommendation: WEAK; 
quality of evidence: LOW).
How sHouLd onE sCrEEn For CAnCEr in psC
There is a high incidence of colorectal cancer in IBD associated 
with PSC. A Swedish population-based study reported a preva-
lence of 7.4%, and other observational studies suggest the cumu-
lative risks are as high as 14%, 31% and 50% at 10, 20 and 25 
years, respectively.204 232 In a meta-analysis of 116 studies, the 
prevalence of colorectal cancer was 3.7% with cumulative risks 
of 2%, 8% and 18% at 10, 20 and 30 years, respectively.62 233 A 
second meta-analysis confirmed an increased risk of colorectal 
cancer in ulcerative colitis associated with PSC and calculated a 
relative risk of 4.79 (95% CI 3.58 to 6.41) in comparison with 
ulcerative colitis without PSC.234 The risk of colorectal cancer in 
patients with ulcerative colitis and concomitant PSC rises further 
(1% a year) for those who have undergone liver transplanta-
tion.180 A case–control study compared 27 patients with PSC 
and IBD-related colorectal cancer with 127 cases of IBD-related 
colorectal cancer without PSC and reported a higher prevalence 
of right-sided cancers (67% vs 36%, p=0.006) in patients with 
PSC.235 A population-based study suggested that PSC-related 
colitis has a 10-fold increased risk of colorectal cancer compared 
with ulcerative colitis without PSC and that screening improves 
outcomes.12 The BSG guidelines for screening and surveillance 
of colorectal cancer in patients with IBD advise that patients 
with colitis and PSC should be screened annually from the time 
of diagnosis, ideally using adjunctive techniques such as dye 
spray to highlight dysplasia.236 Management of dysplastic polyps 
and foci of colonic dysplasia within segments of colitis should 
follow guidance laid out in other guidelines237
There is a lack of data for patients with PSC without colitis, 
but one observational study of 211 patients reported a 10-year 
risk of 2% for the development of colorectal cancer.204 A second 
observational study of 200 patients with PSC also reported three 
cases of colorectal cancer in those without evidence of IBD.201 
Some clinicians undertake 1, 2, 3 or 5 yearly surveillance for all 
patients with PSC, but there is no evidence that outcomes are 
altered using any of these strategies.
There is little evidence to support the use of ERCP to screen 
for CCA. Surveillance with non-invasive imaging, such as ultra-
sound and MRCP, has not been shown to be effective and is not 
routinely recommended. The use of serum tumour markers, 
particularly CA19.9, is widely used, but there is little evidence 
to justify its use for reliable surveillance (see CCA above). Data 
presented in a large cohort of patients with PSC describe the 
limited utility of single and multiple biochemical and imaging 
modalities for the screening of CCA.212
HCC is thought to be uncommon in PSC. A retrospec-
tive cohort of 509 patients with PSC identified a high risk of 
colorectal cancer, CCA and gallbladder cancer, but no reported 
cases of HCC were identified in 119 patients with cirrhosis.231 
One large retrospective study of 830 patients with PSC suggests 
that those underdoing surveillance imaging had earlier diagnosis 
and better 5-year survival rates.238
Even though there are no clear data to support particular 
surveillance methods for each of the main HPB cancer risks in 
patients with PSC, annual transabdominal ultrasonography, in 
addition to other clinically indicated imaging for new symptoms, 
is weakly recommended.
Recommendation 27: We recommend that patients with PSC 
who have coexistent colonic IBD should have annual colono-
scopic surveillance from the time of diagnosis of colitis in line 
with the BSG guidelines (strength of recommendation: STRONG; 
quality of evidence: HIGH). We suggest that those without IBD 
may benefit from less frequent 5-year colonoscopy or earlier 
in the advent of new symptoms (strength of recommendation: 
WEAK; quality of evidence: VERY LOW).
Recommendation 28: We suggest that in the presence of 
cirrhosis, HCC surveillance should be carried out in accordance 
with international guidelines (strength of recommendation: 
WEAK; quality of evidence: LOW).
prEGnAnCy in womEn wiTH psC
Data on pregnancy in PSC are lacking. A German case–control 
series of 229 people with PSC assessed 25 pregnancies in 17 
women and reported no difference in fertility rates or outcomes 
of pregnancy in PSC for either mother or baby compared 
with matched controls.239 However, in this study, 20–32% of 
women with PSC had a rise in liver biochemical tests during and 
after delivery compared with pre-pregnancy levels. A second 
retrospective series of 13 pregnancies in 10 women with PSC 
also reported no significant complications to mother or baby but 
did suggest a higher rate of pruritus during pregnancy, which in 
two cases led to early delivery of the baby.240 In neither series 
were there reports of gastrointestinal bleeding or other compli-
cations of portal hypertension. Data from the Swedish National 
Patient Register, including 229 babies born to women with PSC, 
reported a higher rate of caesarean section and preterm delivery 
but no adverse effect on outcome as measured by size, Apgar 
score or neonatal death.241
As discussed above, long-term UDCA is not routinely indi-
cated for patients with PSC. However, in those women devel-
oping pruritus and worsening cholestasis in pregnancy, there is 
a role for short-term UDCA (10–15 mg/kg) use for symptom-
atic relief owing to the possibility of coexistent intrahepatic 
cholestasis of pregnancy, which has a much higher prevalence 
(1.5% according to a large prospective Swedish study) than PSC 
in pregnant women.242 However, there is no strong evidence to 
support this recommendation and clinicians should judge each 
case individually.
Recommendation 29: We recommend that because preg-
nancy in cirrhotic patients carries a higher risk of maternal and 
fetal complications, patients should have preconception coun-
selling and specialist monitoring (strength of recommendation: 
STRONG; quality of evidence: LOW).
pATiEnT pErspECTivEs And supporT Groups
Patients with PSC are reported to have lower measured phys-
ical and psychological health-related quality of life scores than 
controls—related in part to liver and IBD symptoms as well as 
anxiety, depression and social isolation.198 Dealing with uncer-
tainties about progression of disease and risk of cancer can 
generate considerable anxiety for people diagnosed with PSC. 
The main UK support groups for people with PSC are PSC 
Support ( www. pscsupport. org. uk) and UK-PSC ( www. uk- psc. 
com). The websites provide patient friendly information, support 
forums, lists of liver units and meetings, new developments and 
other items. Patients with IBD should also be encouraged to 
contact related support groups, such as Crohn's & Colitis UK 
( www. crohnsandcolitis. org. uk) and Guts UK ( www. gutscharity. 
org. uk)
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Recommendation 30: We recommend that patients with PSC 
should be encouraged to participate in patient support groups 
(strength of recommendation: STRONG; quality of evidence: 
VERY LOW).
sErviCE sTAndArds And AudiT
PSC can be difficult to manage. Key service standards may assist 
in developing good clinical practice. Clinicians who are uncer-
tain about managing patients with, or complications of, PSC 
should refer them to a specialist clinician or centre for review. 
Key markers of appropriate service standards include:
1. Patients with PSC should have at least an annual clinical as-
sessment. Those with more advanced disease require more 
frequent evaluation and follow-up.
2. Annual blood tests are the minimum baseline investigation, 
with additional tests done as clinically indicated.
3. All patients are screened for the presence of IBD at diagnosis.
4. Clear documentation of the need for surveillance colonos-
copy (depending on presence of IBD) and screening for gall-
bladder pathology and cancer with ultrasound.
5. All patients should have multidisciplinary review before they 
undergo ERCP to minimise unnecessary intervention and 
risk.
6. All patients with suspicion of malignancy should be referred 
to the appropriate MDM. This includes patients with new, 
suspicious or evolving dominant biliary strictures being re-
viewed at the regional specialist HPB MDM to direct appro-
priate investigations and interventions.
7. Patients with evidence of advanced cirrhosis or complica-
tions from complex strictures should be referred to the local 
expert/liver centre.
Future studies
Research into PSC has been mostly through small case series and 
uncontrolled trials in specialist units. Most centres will have an 
insufficient number of patients to affect their clinical service, 
for audit purposes or to undertake independent clinical trials. A 
recent consensus on endpoints for future studies was reported by 
an international PSC working group.243
Studies in progress include investigations into the role 
of norUDCA, farnesoid X receptor agonists, bile salt trans-
porter protein inhibitors, antibiotics and monoclonal antibody 
blockade of receptors thought to be activated in the pathogenesis 
of PSC.244
Gastroenterology units should be encouraged to link patient 
databases in order to improve knowledge of the natural history 
of PSC and response to treatments, and to improve future clin-
ical trials. These efforts should be coordinated by UK-PSC, BSG 
and/or the British Association for the Study of the Liver (BASL) 
and the National Institute for Health Research (NIHR) rare 
diseases initiative. Studies should include a prospective national 
repository of clinical samples. Future clinical trials should be 
registered with the NIHR.
Research and clinical audit questions that may require more 
clarity include:
1. What constitutes a diagnosis of PSC in UK practice?
2. How should patients with unexplained abnormal liver bio-
chemistry and IBD be evaluated, labelled and diagnosed, par-
ticularly when MRCP is normal?
3. How can we improve stratification for risk of (a) liver dis-
ease, (b) disease progression and (c) cancer?
4.  What is the optimal timing and type of intervention for pa-
tients with dominant strictures?
5. Are there any other existing and/or new drugs which may be 
useful in the medical management of PSC?
6. Can we develop a robust database to map the epidemiology, 
progression and management of PSC in the UK as well as to 
assess causes of death?
7. What is the optimal approach to surgical management in pa-
tients with PSC requiring colectomy and/or liver transplan-
tation?
8. Can we report patient perceptions of problems and risks of 
living with PSC with the aim of improving wellbeing for pa-
tients and carers.
ConCLusions
PSC is a complex disease with a wide variation in prognosis. No 
drug treatments alter the outcome of classic PSC, but patients 
with evidence of overlap syndromes, including AIH and IgG4-
SC, may respond to treatment with corticosteroids. Complica-
tions include development of dominant strictures, which may 
respond to endoscopic therapy, and a high risk (up to 1% a 
year) of developing CCA. Those with coexistent colitis should 
undergo annual surveillance colonoscopy. Patients with trouble-
some symptoms, evidence of advanced liver disease (or deemed 
to be at risk of this), jaundice with dominant stenoses, evidence 
of CCA or who express an interest in participating in clinical 
trials should be referred to specialist centres.
iGG4-rELATEd sCLErosinG CHoLAnGiTis
background
Definitions
IgG4-RD is a recently described multisystem disorder charac-
terised by the presence of an IgG4-positive lymphoplasmacytic 
infiltrate in affected organs. It can affect almost any organ (the 
term IgG4-RD is used when referring to general aspects or 
multisystem phenotype of the disease) but most commonly the 
pancreas (type 1 autoimmune pancreatitis/IgG4-related pancre-
atitis (IgG4-RP)) and biliary tract (IgG4-SC). IgG4-SC has been 
classified into four types, with type 1 referring to biliary disease 
confined to the intrapancreatic bile duct (often in association 
with IgG4-RP), and types 2–4 being manifested by various 
degrees of hilar and intrahepatic biliary disease.245
Presentation and disease course
IgG4-SC may present with symptomatic biliary obstruction 
(often manifested as obstructive jaundice), due either to isolated 
biliary disease, but frequently in association with a pancreatic 
mass/diffuse enlargement (IgG4-RP). In a series,246 77% of the 53 
patients with IgG4-SC presented with jaundice, which was associ-
ated with IgG4-RP in 91%. IgG4-SC may develop in 24–39% of 
patients previously diagnosed with IgG4-RP.247 248 Symptomatic 
biliary disease in IgG4-SC does occur in the absence of pancre-
atic disease, and IgG4-SC may also be an incidental finding in 
patients presenting with clinical manifestations of IgG4-RD in 
other organs (eg, kidneys, retroperitoneum, lungs and salivary 
glands). In a UK study of 115 patients with IgG4-RD, 59% had 
IgG4-SC.249 In patients undergoing surgery for presumed hilar 
CCA, pathological features of IgG4-SC, rather than malignancy, 
have been reported in up to 8% of cases.250 The disease course of 
IgG4-SC is poorly defined. Although a recent retrospective study 
of 527 patients followed up for a median of 4 years suggested that 
the disease ran an indolent course,251 other studies have reported 
progression to cirrhosis in 7.7–9% of patients,246 249 and a need 
for liver transplantation has been reported.249 A higher incidence 
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of morbidity, malignancy and mortality in patients with systemic 
IgG4-RD than in age-matched controls has been reported.249
Diagnostic investigations
In clinical practice PSC is one of the most important differential 
diagnoses for IgG4-SC, with others including CCA, and alterna-
tive causes of secondary sclerosing cholangitis (box 1). There are 
no definitive diagnostic tests for IgG4-SC. Serum IgG4 may be 
elevated in 50–80% of patients, and while elevated levels may 
be supportive of the diagnosis they are insufficient in isolation 
to make the diagnosis.252 253 Raised serum IgG4 levels are found 
in only 1% of patients with PBC,26 but elevated serum IgG4 
levels are found in 9–15% of patients with PSC,26 254 making 
distinction between the two diagnoses challenging. An IgG4/
IgG1 ratio of >0.24 may improve the positive predictive value 
and specificity of serum IgG4 measurement in distinguishing 
IgG4-SC from PSC,254 and a serum IgG4 >x4 ULN appears to 
be highly specific for IgG4-SC, compared with IgG4 + PSC.255 
More recently, a blood IgG4/IgG RNA ratio of >5% obtained by 
quantitative polymerase chain reaction on a cohort of 95 patients 
with IgG4-RD, CCA or PSC has been shown to have excellent 
sensitivity (94%) and specificity (99%) for IgG4-RD, although 
this test is not widely available.256
Recommendation 1: We recommend that elevated serum IgG4 
levels support the diagnosis of clinically suspected IgG4-RD but 
cannot be relied on for making a definite diagnosis, or distin-
guishing IgG4-SC from PSC (strength of recommendation: 
STRONG; quality of evidence: MODERATE).
As with PSC, non-invasive imaging should be the corner-
stone of imaging in IgG4-SC. Cross-sectional imaging (CT, 
MRI/MRCP) carries the advantage of allowing definition of the 
pancreaticobiliary ductal system, and also of other organs or 
inflammatory ‘pseudotumours’ which may be involved in IgG4-
RD. PET scanning may identify fluorodeoxyglucose uptake at 
sites distant from the biliary tree characteristic of multisystem 
IgG4-RD (eg, salivary and lachrymal glands), reinforcing the 
diagnostic suspicion of IgG4-SC. However, PET positivity local-
ised only to the biliary tree, and appearances of a ‘pseudotumour’ 
rarely allows definitive distinction from other pathologies, such 
as malignancy. Cholangiography is a central requirement in the 
investigation of all patients with suspected IgG4-SC. As with 
PSC, this should preferentially be by non-invasive means, using 
MRCP. Any part of the biliary tree can be involved in IgG4-
SC, and four characteristic patterns have been defined39: type 
1, stenosis in the lower common bile duct (often in association 
with IgG4-related pancreatitis); type 2a, intrahepatic stenosis 
with prestenotic dilatation; type 2b, intrahepatic stenosis and 
peripheral bile duct pruning; type 3, hilar and lower common 
bile duct stenosis; type 4, hilar stenosis only. MRCP may also 
demonstrate associated pancreatic abnormalities of IgG4-RP, 
including a long pancreatic duct stricture (more than one-third 
of the length of the main duct), multifocal stricturing and lack of 
upstream pancreatic duct dilatation.257
A pathological diagnosis should be pursued in cases of 
suspected IgG4-SC, as this may allow distinction from disease 
mimics (including PSC and CCA). All affected tissues are charac-
terised by similar pathological findings, including an IgG4-pos-
itive lymphoplasmacytic infiltrate, often in association with 
storiform fibrosis and obliterative phlebitis.258 The finding 
of >10 IgG4-positive plasma cells per high power field in endo-
scopic biopsy specimens from the biliary tree (or other affected 
organs) may support a diagnosis of IgG4-SC, with an IgG4+/
IgG + plasma cell ratio >40% providing additional histological 
evidence. Brush cytology does not allow a definitive diagnosis 
of IgG4-SC to be made, but a diagnosis on histology may be 
obtained via fluoroscopically guided endobiliary biopsy, or via 
visually directed cholangioscopic biopsies.259 Biopsies from the 
major papilla are a safe and easy method to obtain tissue; infiltra-
tion of IgG4-positive plasma cells has been reported in 53–80% 
of IgG4-related pancreatitis.260 261 In patients with suspected 
pancreatic and biliary disease associated with IgG4-RD, endo-
scopic ultrasound-guided, fine-needle aspiration cytology is 
effective in excluding malignancy, but rarely allows a definitive 
diagnosis of IgG4-RD.262 A core biopsy may provide more defin-
itive pathological evidence.
Recommendation 2: We recommend that in patients with 
suspected IgG4-SC, attempts should be made to obtain a confir-
matory histological diagnosis (strength of recommendation: 
STRONG; quality of evidence: MODERATE).
Differentiating IgG4-related sclerosing cholangitis from PSC
In clinical practice the most common challenge is differen-
tiating IgG4-SC from either PSC or CCA. The presence on 
cross-sectional imaging of other organ manifestations of IgG4-
RD, including the pancreas, kidneys, and retroperitoneum, may 
point towards a diagnosis of IgG4-SC, as opposed to PSC or 
CCA.13 263–265 IgG4-SC can occur in isolation, but has been 
reported in association with type 1 autoimmune pancreatitis 
(IgG4-RP) in >80% of cases.246 266 
As outlined, MRCP is a useful non-invasive test in the investi-
gation of possible IgG4-SC. Features such as long strictures with 
prestenotic dilatations, the absence of peripheral duct pruning 
and a lack of biliary pseudodiverticulae are more suggestive of 
IgG4-SC than PSC.39 However, a multicentre study of cholan-
giograms in patients with PSC, CCA or IgG4-SC, demonstrated 
that, even among specialists, a correct diagnosis by interpreta-
tion of cholangiography alone is difficult and unreliable, with a 
high interobserver variation.40 Certain features appear to help 
differentiate IgG4-SC from PSC, including the much higher 
prevalence of IBD in PSC (approximately 70%) compared 
with IgG4-SC (5.6% in 71 patients with autoimmune pancre-
atitis/IgG4-SC),267 and predominance of pancreatic disease and 
extra-gastrointestinal involvement in IgG4-SC (see table 2).
Although an IgG4-positive lymphoplasmacytic infiltrate may 
be found in liver biopsy specimens from patients with PSC, it 
Table 2 Clinical parameters in differentiating IgG4-related sclerosing 
cholangitis (IgG4-SC) from primary sclerosing cholangitis (PSC)
Clinical feature supportive of igG4-sC 
or psC psC igG4-sC
Male sex + ++
Younger age ++ +
Pancreatic mass or enlargement on CT − ++
Pancreatic ductal abnormalities +/- +++
Raised serum IgG4 +/- ++
Ampullary biopsy with >10 IgG4 plasma 
cells per high power field
− +++
Liver/tissue biopsy with >10 IgG4 plasma 
cells per high power field
+/− +++
Pancreatic exocrine insufficiency − ++
Other associated systemic fibrosclerotic 
disease
− ++
Cholangiographic changes ++ ++
Presence of inflammatory bowel disease ++ +/− 
Improvement with steroid treatment +/− +++
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rarely reaches the concentration of >10 IgG4-positive plasma 
cells per high power film often seen in IgG4-SC.268 Where there 
is a possibility that strictures are related to IgG4-SC, endoscopic 
ampullary biopsy sampling should be considered with immu-
nostaining for IgG4, which may be present in 52–72% of cases 
of IgG4-RD,269 270 and may facilitate discrimination between 
IgG4-SC and PSC.271
A characteristic feature of IgG4-RD and IgG4-SC is that of 
a prompt clinical and radiographic response to steroid treat-
ment (although subsequent relapse may occur in >40% of 
cases).246 266 This is in stark contrast to PSC in which routine 
steroid use ordinarily provides no therapeutic benefit. Neverthe-
less, in one study of 285 patients with PSC, raised serum IgG4 
was found in 33 (12%), and these patients underwent steroid 
treatment.59 Although improvement in bilirubin occurred in 
90% (despite cirrhosis in 50%), relapse occurred in 50% after 
an initial favourable response, and complications from steroids, 
or progression of liver disease, were common.
Recommendation 3: We recommend that other organ involve-
ment (in particular, pancreatic manifestations of IgG4-RD) may 
provide important information to distinguish IgG4-SC from PSC 
(strength of recommendation: STRONG; quality of evidence: 
MODERATE).
Recommendation 4: We recommend that IgG4-SC should 
be diagnosed according to the recommendations of the inter-
national consensus guidelines (strength of recommendation: 
STRONG; quality of evidence: MODERATE).
Treatment
There are few randomised placebo-controlled data to guide 
treatment of IgG4-SC (or IgG4-RD in general), but large case 
series have reported rapid and favourable disease control after an 
initial course of steroids. A common steroid regimen used in the 
UK is oral prednisolone 40 mg daily for 2–4 weeks, subsequently 
reduced by 5 mg every week over approximately 8–12 weeks. 
The effect is measured by clinical response (eg, resolution of 
jaundice, liver biochemistry, etc) and radiological findings such as 
resolution of mass lesions and improvement in cholangiopathy. 
Lack of objective improvement in radiological abnormalities on 
repeat imaging at weeks 4–8 suggests either an incorrect diag-
nosis or a fibrotic, non-inflammatory phase of disease. Although 
serum IgG4 often falls in response to steroids, its level is not 
used to monitor or plan further treatment. Relapse after cessa-
tion of steroid treatment may occur in at least 60% of patients 
with IgG4-SC, and is more common in those with multiorgan 
involvement. To date, practice in Europe and North America has 
often been to introduce an immunomodulator (eg, azathioprine, 
mercaptopurine or mycophenolate) with further steroids if there 
is evidence of relapse,266 272 or a high risk of relapse. There is no 
clear consensus on dosing regimens, including the need to main-
tain low dose steroids in those receiving azathioprine (usually 
at a dose of 2 mg/kg/day). Japanese experts favour maintenance 
steroid treatment, and a recent randomised study (in IgG4-RD, 
rather than specifically IgG4-SC) showed lower rates of relapse 
at 3 years in those treated with maintenance prednisolone 
5–7.5 mg (23%) than in those given an initial steroid withdrawal 
regimen (58%).273 Emerging evidence from case series suggest 
that >95% of these patients with IgG4-RD will respond to 
biological therapy using anti-CD20 monoclonal antibodies such 
as rituximab.272 Rituximab is likely to be the preferred treatment 
for patients who fail to respond to first- or second-line treatment 
or whose disease flares on withdrawal of steroids, particularly 
in those with multisystem or complex disease. Small studies 
have suggested the efficacy of rituximab in patients with IgG4-
SC.274 275 Given the complexity of management it is advisable 
for patients with possible IgG4-SC to be referred to specialists or 
centres with experience of the disease to establish the diagnosis, 
plan management and recruit into trials.
Recommendation 5: We recommend that patients with 
active IgG4–SC should be given corticosteroids as first-line 
treatment (strength of recommendation: STRONG; quality of 
evidence: MODERATE).
Recommendation 6: We recommend that all patients with 
IgG4-SC, including those with multiorgan involvement in IgG4-
RD, should be considered for continued immunosuppressive 
therapy (strength of recommendation: STRONG; quality of 
evidence: MODERATE).
Recommendation 7: We recommend that patients with 
complex IgG4-SC and those with suspected malignancy should 
be referred to a specialist MDM for review (strength of recom-
mendation: STRONG; quality of evidence: LOW).
Audits and future studies
Research in the field of IgG4-SC/IgG4-RD has increased signifi-
cantly over the past 10 years, initially in small case series and 
uncontrolled trials in specialist units. Most centres will have an 
insufficient number of patients to affect their clinical service, 
for audit purposes or to undertake independent clinical trials. 
Gastroenterology units should be encouraged to link patient data-
bases in order to improve knowledge of the natural history and 
response to treatments, and to improve future clinical trials.
Research and clinical audit topics that may require more 
clarity include:
1. The aetiopathogenesis of IgG4-RD.
2. Development of a robust database to map the epidemiology, 
progression and management of IgG4-RD in the UK and to 
assess causes of death.
3. The optimal medical management for patients with IgG4-SC.
4. Reporting of patient perceptions of problems and risks of 
living with IgG4-RD.
ConCLusions
IgG4-SC falls within the spectrum of a multiorgan fibroinflam-
matory disease (IgG4-RD). It requires distinction from other 
causes of biliary stricturing, particularly PSC and biliary malig-
nancy, as improvement may be seen with steroids and other 
immunosuppressant agents. The risk of cancer appears to be 
low, unlike for patients with PSC. There are insufficient data 
to recommend surveillance for cancer. Patients with IgG4-SC 
should be considered for referral to specialist centres.
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